

**Department of Oral and Maxillofacial Diseases,**  
Helsinki University Central Hospital (HUCH), University of Helsinki, Helsinki, Finland  
**Oral Pathology Unit / Laboratory Diagnostics,**  
Helsinki University Central Hospital (HUCH), Helsinki, Finland, and  
**Department of Oral Pathology,**  
Institute of Dentistry, University of Helsinki, Helsinki, Finland  
**Department of Diagnostics and Oral Medicine,**  
Institute of Dentistry, University of Oulu, Oulu University Hospital, Oulu, Finland

# **Matrix metalloproteinases in pulpitis, chronic apical periodontitis and odontogenic jaw cysts**

**Jaana Wahlgren**

Academic Dissertation

*To be presented with the permission of the Faculty of Medicine,  
University of Helsinki, for public discussion in the main auditorium of the  
Institute of Dentistry, Mannerheimintie 172, Helsinki  
On October 10<sup>th</sup>, at 12 noon*

**Helsinki 2003**

**Supervised by:**

Professor **Tuula Salo**, DDS, PhD,  
Department of Diagnostics and Oral Medicine, University of Oulu, Oulu University Hospital,  
Oulu, Finland

Professor **Jarkko Hietanen**, DDS, MD, PhD,  
Oral Pathology Unit / Laboratory Diagnostics, Helsinki University Central Hospital (HUCH)  
and Department of Oral Pathology, Institute of Dentistry, University of Helsinki, Helsinki,  
Finland

Associate Professor **Olli Teronen**, DDS, PhD  
Department of Oral and Maxillofacial Diseases, Helsinki University Central Hospital  
(HUCH), University of Helsinki, Helsinki, Finland

Professor **Timo Sorsa**, DDS, PhD, Dipl Perio  
Department of Oral and Maxillofacial Diseases, Helsinki University Central Hospital  
(HUCH), Oral Biology-section, Institute of Dentistry, University of Helsinki, Helsinki,  
Finland

**Reviewed By:**

Associate Professor **Tuula Ingman**, DDS, PhD,  
Department of Pedodontics and Orthodontics, Institute of Dentistry, University of Helsinki,  
Helsinki, Finland

Professor **Ylermi Soini**, MD, PhD,  
Department of Pathology, University of Oulu, Oulu University Hospital, Oulu, Finland

**Opponent:**

Associate Professor **Gareth Thomas**, DDS, PhD  
Department of Oral Pathology, Eastman Dental Institute, London, UK

**to my family**

## Contents

List of original publications	6
Abbreviations	7
Abstract	9
1 Introduction	10
2 Review of the Literature	11
2.1 Dental pulp	11
2.1.1 Odontoblasts	11
2.2 Pulpal and periapical pathology and treatment	13
2.2.1 Pulpitis	13
2.2.2 Apical periodontitis	14
2.2.3 Root canal treatment	15
2.3 Odontogenic cysts	17
2.3.1 Radicular cyst	17
2.3.2 Follicular cyst	18
2.3.3 Odontogenic keratocyst	18
2.4 Plasma cells	20
2.4.1 Multiple myeloma and plasmacytoma	20
2.5 Laminin-5	22
2.6 Matrix metalloproteinases	22
2.6.1 Collagenases	23
2.6.2 Gelatinases	26
2.7 Regulation of MMPs	26
2.7.1 Transcriptional regulation of MMP expression	26
2.7.2 MMP activation	27
2.7.3 MMP inhibition	29
3 Aims and outlines of the study	32
3.1 Aims of the study	32
3.2 Outlines of the study	32
4 Materials and methods	33
4.1 Patients and tissue samples	33
4.1.1 Pulp tissue and odontoblasts	33
4.1.2 Patients and diagnosis	33
4.1.3 Tissue specimens	34
4.2 Cells and culture methods	34
4.2.1 Odontoblasts and pulpal cells	34
4.2.1.1 Odontoblast cultures	34
4.2.1.2 Pulp fibroblast cultures	35
4.2.2 Plasma cells	35
4.3 Sample collection from root canals	35
4.4 PCR analysis	36
4.4.1 RNA isolation	36
4.4.2 RT-PCR	36
4.5 Southern blotting	36
4.6 Western immunoblotting and MMP-8 immunofluorometric assay	37
4.6.1 Western immunoblot analysis	37
4.6.2 MMP-8 immunofluorometric assay	37
4.7 Preparation of cRNA probes	37
4.8 <i>In situ</i> hybridization	38

4.9	Immunohistochemical staining and evaluation of the staining	38
4.9.1	Immunostaining	38
4.9.2	Evaluation of immunostaining	38
4.10	Statistical analysis	39
5	Results	40
5.1	Pulpal and periapical tissue	40
5.1.1	MMP-8 in odontoblasts and pulp tissue	40
5.1.1.1	Healthy pulp tissue	40
5.1.1.2	Pulp with inflammation	40
5.1.2	MMP-8 in the root canal exudate	40
5.1.3	MMPs in apical periodontitis	41
5.2	Odontogenic cysts	41
5.2.1	Laminin-5	41
5.2.2	Expression of MMP-2	41
5.2.3	Expression of MMP-8	41
5.2.4	Expression of MMP-9	42
5.2.5	Expression of MMP-13	42
5.3	Multiple myeloma and plasmacytoma	42
5.3.1	Plasmacytoma tissue samples	42
5.3.1.1	MMP-8	42
5.3.1.2	MMP-13	42
5.3.2	Multiple myeloma cell cultures	42
5.3.2.1	MMP-8 expression	43
5.3.2.2	MMP-13 expression	43
6	Discussion	44
6.1	The role of MMPs in pulpal and periapical tissue, and root canal exudate	44
6.1.1	MMPs in pulp tissue	44
6.1.2	MMPs in periapical tissue and root canal exudate	44
6.2	MMPs and Ln-5 in odontogenic cysts	45
6.3	MMPs in multiple myeloma	47
7	Conclusions	48
	Acknowledgements	49
	References	51

## List of Original Publications

**This thesis is based on the following publications, referred to in the text by their Roman numerals:**

- I.** Palosaari H, Wahlgren J, Larmas M, Rönkä H, Sorsa T, Salo T, Tjäderhane L. The expression of MMP-8 in human odontoblasts and dental pulp cells is down-regulated by TGF- $\beta$ 1. *J Dent Res* 2000; 79: 77-84.
- II.** Wahlgren J, Salo T, Teronen O, Luoto H, Sorsa T, Tjäderhane L. Matrix-metalloproteinase-8 (MMP-8) in pulpal and periapical inflammation and periapical root canal exudates. *Int Endod J* 2002; 35: 897-904.
- III.** Wahlgren J, Väänänen A, Teronen O, Sorsa T, Pirilä E, Hietanen J, Maisi P, Tjäderhane L, Salo T. Laminin-5 gamma 2 chain is colocalized with gelatinase A (MMP-2) and collagenase-3 (MMP-13) in odontogenic keratocysts. *J Oral Pathol Med* 2003; 32: 100-107.
- IV.** Wahlgren J, Maisi P, Sorsa T, Sutinen M, Tervahartiala T, Pirilä E, Teronen O, Hietanen J, Tjäderhane L, Salo T. Expression and induction of collagenases (MMP-8 and MMP-13) in plasma cells associated with bone-destructive lesions. *J Pathol* 2001; 94: 217-224.

## Abbreviations

AAP	acute apical periodontitis
AEC	3-amino-9-ethylcarbazole
AP	activation protein
$\alpha$ 1AC	$\alpha$ 1-antichymotrypsin
$\alpha$ 1PI	$\alpha$ 1-proteinase inhibitor
$\alpha$ 2M	$\alpha$ 2-macroglobulin
BAG	bacterial antigens
bp	base pair
BM	basement membrane
CAP	chronic apical periodontitis, periapical granuloma
cDNA	complementary DNA
CMT	chemically modified non-antimicrobial tetracyclins
DAB	3,3-diaminobenzidine tetrahydrochloride
DEPC	diethylpyrocarbonate
DIG	digoxigenin
DMEM	Dulbecco's modified Eagle's medium
ECM	extracellular matrix
EDTA	ethylene diamino tetra acetic acid
EGF	epidermal growth factor
FBS	foetal bovine serum
FC	follicular cyst
FGF	fibroblasts growth factor
FN	fibronectin
GCF	gingival crevicular fluid
Gly	glycine
IFN	interferon
Ig	immunoglobulin
IGFBPs	insulin-like growth factor binding proteins
kDa	kilodalton
KC	keratocyst
IL	interleukin
Ile	isoleusine
Leu	leusine
Ln	laminin
LPS	lipopolysaccharide
MM	multiple myeloma
MMP	matrix metalloproteinase
MMPI	matrix metalloproteinase inhibitor
mRNA	messenger RNA
MT-MMP	membrane type matrix metalloproteinase
Ob	osteoblast
Oc	osteoclast
PBS	phosphate-buffered saline
PCNA	proliferating cell nuclear antigen
PCR	polymerase chain reaction
PEA	polyoma virus enhancer A binding protein
PF	pulp fibroblast
PGE	prostaglandin
PISF	peri-implant sulcular fluid
PLC	plasmacytoma
Plc	plasma cell
PMA	phorbol myristate acetate
PMN	polymorphonuclear leukocyte
PTCH	patched tumour suppressor gene
RC	radicular cyst
RCT	root canal treatment

SCC	squamous cell carcinoma
SDS	sodium dodecyl sulphate
SSC	saline-sodium citrate
TAT	tumour-associated trypsin
TGF	transforming growth factor
TIE	TGF $\beta$ inhibitory element
TIMP	tissue inhibitor of metalloproteinase
TNF	tumour necrosis factor
VN	vitronectin

## Abstract

Matrix metalloproteinases (MMPs) form an enzyme family capable of degrading almost all extracellular matrix (ECM) and basement membrane (BM) components. They play an important role in normal tissue remodelling and growth, as well as in many destructive pathological conditions such as inflammation, tumour growth and metastasis.

The expression of MMP-8 in cultured human mature pulpal cells and odontoblasts was evaluated with polymerase chain reaction-method (PCR). Mesenchyme-derived cells, pulp tissue cells and odontoblasts expressed MMP-8, which was down-regulated by transforming growth factor  $\beta$  (TGF- $\beta$ ) in these cell cultures. Immunohistochemical staining revealed MMP-8 protein in the odontoblasts. These results suggest that MMP-8 may participate in dentin matrix organization during dentin formation.

The presence of MMP-8 in inflammatory pulpal and periapical tissues and in root-canal exudate during root-canal treatment was further studied. Using immunohistochemistry, MMP-8 staining was detected in polymorphonuclear leukocytes (PMNs), macrophages and plasma cells in both pulpal and periapical lesions. MMP-8 has evidently a role in pulpal and periapical inflammation. MMP-8 levels in periapical exudate were significantly reduced during root canal treatment. Measuring MMP-8 levels in periapical exudate may be used as a biochemical indicator/molecular marker to monitor the inflammatory activity and success in root canal treatment.

Odontogenic keratocyst (KC) has special characteristics; its epithelium proliferates rapidly and detaches easily from connective tissue stroma, it recurs easily and forms daughter cysts. With this background, the differential expression of MMPs in odontogenic cysts was studied. The results revealed colocalization of MMP-2 and MMP-13 with laminin-5 (Ln-5)  $\gamma$ 2-chain in the KC basement membrane zone indicating that especially these MMPs may be responsible for the epithelial detachment of KC.

In all odontogenic cysts, MMP-8 protein was detected not only in PMNs, but also macrophages and plasma cells by immunohistochemistry. *In situ* hybridization showed MMP-8 mRNA expression in the plasma cells of follicular cyst (FC). MMP-13 expression was also localized to plasma cells in periapical lesions, KCs and plasmacytoma (PLC) specimens by both immunohistochemical staining and *in situ* hybridization.

Cultured multiple myeloma cells showed that the expression of MMP-8 and MMP-13 was enhanced by phorphol-12-myristate-13-acetate (PMA) and heparin combined with different cytokines like interleukin-6 (IL-6).

Overall, these results show that MMPs play an important role in ECM and BM remodelling and destruction during dentin formation, inflammatory processes of pulpitis, apical periodontitis, and enlargement of odontogenic jaw cysts, as well as reflect the special characteristics of them.

## 1. Introduction

MMPs form a group of proteases able to degrade most ECM and BM components (Kähäri and Saarialho-Kere 1999). MMPs are divided according to their substrate specificities and structures to interstitial collagenases, gelatinases, membrane-type MMPs, stromelysins, matrilysins and other MMPs. MMPs are important in physiological growth and tissue remodelling. Their role in tissue destructive pathological conditions is evident but still however not completely clarified. MMP expression is regulated by proinflammatory cytokines and growth factors as well as ECM components. The collagenases include MMP-1 (collagenase-1), MMP-8 (collagenase-2) and MMP-13 (collagenase-3), and the gelatinases (type IV collagenases) include MMP-2 (gelatinase A) and MMP-9 (gelatinase B). Collagenases and gelatinases, being able to break collagens and laminins, are considered to be the key MMPs responsible for ECM and BM destruction in many pathological conditions. (Vu and Werb 2000, Sternlicht and Werb 2001).

MMPs have recently been found also in pulpal tissue and odontoblasts, where they play a role in dentin matrix formation and modulation during caries progression and secondary dentin formation (Llano *et al* 1997, Tjäderhane *et al* 1998). The role of MMPs in pulpal and periapical inflammation is still unclear.

In order to expand odontogenic cysts need to destroy the surrounding bone and other tissues. MMPs take part in these tissue destructive cascades. Gelatinases and collagenases have been found in jaw cyst fluids and tissues (Teronen *et al* 1995a, b). KCs exert special characteristics (epithelial detachment and high recurrence rate) among the odontogenic jaw cysts. The reasons for these special qualities of the KC are not yet clarified (Neville *et al* 2002). Solitary bone PLC and multiple myeloma (MM) are malignant destructive pathological conditions of the bone. They are caused by pathologically growing plasma cells of monoclonal origin (Neville *et al* 2002). MM cells express gelatinases and MMP-1 and their expression is up-regulated during the active phase of MM disease (Vacca *et al* 1999, Ria *et al* 2002).

In this investigation, the *in vivo* expression of collagenase MMP-8 in pulpal and periapical tissue was studied. The expression of collagenases, MMP-8 and MMP-13 and gelatinases, MMP-2 and MMP-9, was further studied in odontogenic cysts and plasmacytomas. The *in vitro* expression of MMP-8 in odontoblasts and MMP-8 and -13 in malignant plasma cell cultures activated by PMA, heparin and different cytokines was also studied. In addition, the expression of MMP-2, -8, -13 and Ln-5 in the epithelium of KCs was investigated. The methods used were cell culture, *in situ* hybridization, immunohistochemistry, Western blot, Southern blot, immunofluorometric assay and PCR-analysis.

## 2. Review of the Literature

### 2.1 Dental pulp

The pulpal tissue is mainly composed of cells, loose connective tissue and ground substance. The main cellular components are fibroblasts, odontoblasts, undifferentiated cells and defence cells. Major extracellular components are mature and immature collagen fibres, mainly collagen I and III, produced by pulpal fibroblasts and odontoblasts. The connective tissue of the pulp lacks elastic fibres. The ground substance in the pulp consists of hyaluronic acid, chondroitin sulphate, glycoproteins, carbohydrates and water. The pulp organ is well vascularised and contains nerve bundles. From its periphery to centre the pulp consists histologically of the odontoblast layer, cell-free zone of Weil, cell-rich zone, and pulp core (Fig. 1). The relations of these different zones vary depending on the age of the pulp. (Okiji 2002).

#### 2.1.1 Odontoblasts


Odontoblasts, next to fibroblasts, are the second most prominent cells in the pulp tissue. The odontoblast cell processes extend to dentinal tubules while the odontoblast body is adjacent to the predentin in the pulp (Fig.1). The odontoblast location is called the odontogenic zone of the pulp. In the odontoblastic row, the cells lie close to each other and the adjacent cells are connected by three types of intercellular junctions: impermeable (tight), adhering and communicating (gap) junctions. A capillary network surrounds the odontoblasts. Odontoblasts are highly differentiated mesenchymal cells incapable of proliferating and their main function is to produce dentin. The cell body is responsible of the synthesis of matrix glycoproteins, collagens and ground substance, while the odontoblastic process that extends into the dentinal tubules is the secretory organ (Fig. 1). (Okiji 2002).

The main collagen produced by odontoblasts is collagen I, but they also produce type III collagen mRNA (Lukinmaa *et al* 1992, 1993), and cultured odontoblasts secrete type I and III collagen (Tjäderhane *et al* 2001). In addition to tissue-building-components odontoblasts express tissue destructive enzymes, MMPs, indicating a role for MMPs in the dentin organic matrix remodelling (Tjäderhane *et al* 1998, 2001). They secrete at least gelatinase-A (MMP-2), gelatinase-B (MMP-9), collagenase-2 (MMP-8), collagenase-3 (MMP-13), enamelysin (MMP-20) and membrane type matrix metalloproteinase-1 (MT1-MMP) (Tjäderhane *et al* 2001, Palosaari *et al* 2002). MMPs can contribute to the dentin matrix modulation in the reparative dentin production and in caries progression (Tjäderhane *et al* 2001).

**Figure 1. Odontoblasts in the predentin-pulp zone.**

Odontoblasts lie partly bedded in the dentin in the odontogenic zone. The cell-free zone and the cell-rich zone are located in the pulp area.

(Modified from Walton and Torabinejad 1996)



## 2.2 Pulpal and periapical pathology and treatment

Irritation and injury of pulpal tissues leads to inflammation called pulpitis. Untreated pulpitis may lead to pulp necrosis and, associated with the root canal infection finally lead to apical periodontitis, destruction of the bone surrounding the root apex of the affected tooth. If the apical inflammation is not eliminated it can cause more severe conditions, such as apical abscesses, radicular cysts and osteomyelitis. (Neville *et al* 2002).

### 2.2.1 Pulpitis

Pulpal inflammation is caused by microbes, and mechanical or chemical irritants.

The pulp tissue injury causes cellular damage and the release of nonspecific proinflammatory mediators *e.g.*, histamine, bradykinin, neurokinins, neuropeptides and prostaglandins. These factors cause vasodilatation, increased blood flow, exudate formation and edema. Rigid walls surround the pulp and the lack of lymphatic vessels can lead to arterial compression and tissue necrosis due to the pressure caused by inflammatory edema. The pulpal inflammation usually progresses slowly. Blood stasis leads to increased red blood cell aggregation, blood viscosity and CO<sub>2</sub> levels, as well as decreased pH levels and waste product removal. (Walton and Torabinejad 1996, Fouad 2002). Carious enamel and dentin contain numerous bacteria capable of eliciting inflammatory reactions in pulp. These reactions are not often caused by direct exposure to bacteria, but instead to their virulence factors or their toxins that penetrate via dentinal tubules into the pulp (Walton and Torabinejad 1996).

The pulpal pathology may range from local inflammation (reversible pulpitis) to irreversible pulpitis, which can proceed to total root canal necrosis. **Chronic hyperplastic pulpitis** (pulp polyp) is a unique pattern of pulpal inflammation occurring in young adults and children who have large exposure of pulp with even the entire dentinal roof missing. **Reversible pulpitis** is characterized by hyperemia, increased permeability of blood vessels (Takahashi 1990) and edema in the pulp, as well as chronic inflammatory infiltrate underlying the affected dentinal tubules. Clinical manifestations show mild-to-moderate pain of short duration. Different stimuli (cold, hot, sweet and sour) activate the pain that usually disappears when the stimulus is not present. Mobility and sensitivity to percussion are mostly absent. (Walton and Torabinejad 1996, Neville *et al* 2002). **Irreversible pulpitis** is usually sequela of reversible pulpitis associated with a higher level of inflammation at a stage where recovery is impossible. Histologically irreversible pulpitis often shows a crush in the venules resulting in focal necrosis. PMN cells and histiocytes dominate in these necrotic areas. It is worth noting that, irreversible pulpitis may process without any symptoms. If pain is present it may be spontaneous or continuous. In early irreversible pulpitis the sharp and severe pain continues even after stimuli are removed. In the early stage of pulpitis the tooth responds to the pulp vitality testing at lower levels and in the later inflammatory stage at higher levels or not at all. In the later stages of irreversible pulpitis, the pain becomes constant and very intense; however, cold may produce relief by causing vasoconstriction and a drop of pulpal pressure. The percussion sensitivity and mobility may be absent because the inflammation has not yet spread outside the tooth apex. (Walton and Torabinejad 1996, Neville *et al* 2002).

The bacterial antigens and lipopolysaccharides (LPS) in the infected pulp increase the levels of immunoglobulins, prostaglandins and other proinflammatory mediators (Nakanishi *et al* 1995). In pulpal reaction, the bacterial components and inflammatory factors can stimulate the neutrophil degranulation and secretion by monocytes/macrophages (Morand *et al* 1981, McClanahan *et al*

1991, Cootauco *et al* 1993, Panagakos *et al* 1996, O'Boskey and Panagakos 1998, Chang *et al* 2001, Lu *et al* 2002). The released IL-1 and tumour necrosis factor- $\alpha$  (TNF- $\alpha$ ) are able to induce MMP-1, MMP-2 and the tissue inhibitor of metalloproteinases-1 (TIMP-1) gene expression in pulpal cells (Chang *et al* 2001, Lin *et al* 2001). Stimulation by black-pigmented *Bacteroides* elevates MMP-2 production (Chang *et al* 2002), and anaerobic bacterial extracts provoke pulp cells to excrete MMP-1 and MMP-2 as well as TIMP-1 (Nakata *et al* 2000). The levels of MMP-1, -2 and -3 are statistically significantly higher in acute pulpitis than in normal pulp tissue (Shin *et al* 2002). The treatment of pulpitis varies from the removal of the local irritant, pulp capping to pulpectomy and root canal treatment or even extraction of the tooth depending on the severity of pulpitis.

### 2.2.2 Apical periodontitis

If pulpitis remains untreated and bacteria invade the pulp cavum and pulpal tissue it finally leads to apical periodontitis, which represents a protective and destructive inflammatory reaction also involving the bone surrounding the tooth apex. The infection in root canal is usually a mixed infection with anaerobic domination (Haapasalo 1989).

In **acute apical periodontitis (AAP)**, the pulp may be irreversibly inflamed or necrotic and it contains PMNs and monocyte/macrophages-like cells within a localized area at the apex. The bone and root resorption is not yet extensive enough to be detected in radiographs. If not treated AAP develops into **chronic apical periodontitis (CAP, periapical granuloma)** leading to pulp necrosis and bacterial toxins invading into the apical zone. The host defence responds to these bacterial root canal exudates and a defensive granulation zone is formed. If the bacteria persists in the root canal and, despite the defence responses, invade outside the root apex, the lesion may progress into an abscess with or without fistulation. (Neville *et al* 2002).

Histologically CAP is made up of inflamed granulation tissue surrounded by a fibrous connective tissue wall. CAP is most often infiltrated by lymphocytes, plasma cells, monocytes/macrophages, as well as PMNs, and less frequently, mast cells, eosinophils and foam cells. (Neville *et al* 2002). A collection of Russell bodies, scattered eosinophilic globules of gammaglobulins, may be seen if numerous plasma cells are present, as well as lightly basophilic particles (pyronine bodies). These plasma cell products may be found in any accumulation of plasma cells and are not specific for CAP. Cholesterol clefts associated with multinucleated foreign body giant cells and red blood cell areas with hemosiderin pigmentation can sometimes be found and small abscess formation with acute inflammation may be present. (Walton and Torabinejad 1996, Neville *et al* 2002).

Most CAPs are asymptomatic with just a little discomfort and CAP is usually discovered in routine radiographic examination: radiolucency is present and the affected tooth lacks apical lamina dura. The tooth does not respond to electric vitality testing because the pulp is necrotic and the percussion sensibility is mild at most. (Walton and Torabinejad 1996, Neville *et al* 2002). The immune-inflammatory process in apical periodontitis is double-faced. On the one hand, it is a protective host response to prevent bacterial invasion of the tooth apex and surrounding bone tissue, but, on the other the "protective" mechanism also leads to destruction of the host tissue components (Márton and Kiss 2000). The first barrier to prevent bacterial invasion through apical foramen is provided by PMNs, which, by active phagocytosis and killing, effectively keep the bacterial amount and penetration as low as possible. Monocytes/macrophages also take part in the primary phagocytic protective phase and secrete antigens to act as chemotactic stimuli and to recruit other cells to participate in the inflammatory reaction (Márton and Kiss 2000). The degradation of the mineralised matrix of the alveolar bone surrounding the tooth apex is due to the action of osteoclasts (Bohne 1990, Anan *et al* 1991). In inflammation the delicate balance between osteoclasts and osteoblasts is disturbed resulting in bone loss. There are many factors

that have a stimulating effect on bone resorption in the apical periodontitis (Fig. 2). These stimulating factors include bacterial components, mainly LPS like endotoxin and short-chain fatty acids, released to the apical area, as well as host-derived substances. The host-defence system stimulates the tissue destructive reactions by releasing arachidonic acid derivatives (prostaglandins and leukotrienes) during phagocytosis and other cell-mediated inflammatory factors, such as cytokines. High levels of immunoglobulins, secreted by plasma cells, are also found in periapical lesions (Torres *et al* 1994, Matsuo *et al* 1995, Miyauchi *et al* 1996). Other plasma proteins, such as complement components, bradykinin, kallikrein and thrombin and acute-phase reactants, derived from dilated blood vessels are also present to stimulate bone resorption (Lerner 1994, Márton and Kiss 2000). As a response to stimuli, monocyte/macrophage-like cells, plasma cells, fibroblasts, epithelial and endothelial cells, PMNs, osteoblasts and osteoclasts in periapical periodontitis can produce bone resorptive cytokines IL-1 $\alpha$  and IL-1 $\beta$ , TNF- $\alpha$  and IL-6 (Artese *et al* 1991, Piattelli *et al* 1991, Barkhordar *et al* 1992, Miller *et al* 1996, Márton and Kiss 2000). T-cells express IL-2, IL-4, IL-6, IL-10 and interferon- $\gamma$  (IFN- $\gamma$ ), and B-cells, fibroblasts and monocyte/macrophage-like cells IL-10 (Walker *et al* 2000). The immune cytokines in CAP can accelerate bone resorption (Stashenko 1990). The tissue destructive process is interactive, and these cytokines can trigger other cells to express proteolytic enzymes, including MMPs, also found to be present in periapical granulation tissue (Barkhordar 1987, Takahashi 1998).(Fig. 2.).


### 2.2.3 Root canal treatment (RCT)

In order to eliminate the pulpal inflammation to avoid root canal necrosis, prevent or heal periapical periodontitis root canal treatment (RCT) has to be performed. The aim of RCT is to remove bacteria and their toxins from the root canal by mechanical and chemical cleaning. The root canal treatment techniques vary according to the person. The treatment needs to be done under aseptic conditions and therefore the tooth is separated from other teeth and the oral cavity by a rubber dam and the working area is sterilized. The first step in RCT is to determine the working length of the root canal instruments, which is often done by radiographs and/or by electrical measuring. The necrotic tissue is removed with special root canal instruments and the canal is mechanically widened using rinsing with antiseptic liquids and usually also with liquids, like ethylene diamino tetra acetic acid (EDTA), to remove the smear layer from the root canal walls. Root filling is done during the same appointment or the next visit. An X-ray is taken to check the root filling. The success of the treatment is usually checked within one year of the basic treatment. It is considered successful if no clinical symptoms remain and the periapical area in a radiological examination seems to be normal without signs of inflammation or resorption. (Walton and Torabinejad 1996). The difficulty during RCT is to determine whether the treatment has been successful enough to eliminate the bacteria in the root canal environment. If not, it is likely that the infection in the apical area persists. Chair-side adjunctive diagnostic tests measuring the inflammatory level or mediators of periapical tissue are suggested as future tools in endodontics (Metzger 2000).

## Figure 2. The bone destructive mechanism in apical periodontitis.

This figure shows the complicated network of tissue reactions against bacterial products in apical periodontitis. (Modified from Márton and Kiss 2000)

BAG: bacterial antigens, LPS: Lipopolysaccharides, PMN: polymorphonuclear leukocyte, T: T-lymphocyte, B: B-lymphocyte, Mc: macrophage, Fb: fibroblast, Plc: plasma cell, Ob: osteoblast, Oc: osteoclast, TNF: tumour necrosis factor, IL: interleukin, INF: interferon, PGE: prostaglandin, MMP: matrix metalloproteinase.



## 2.3 Odontogenic cysts

“A cyst is described as a pathological cavity, lined usually totally or partly with epithelium, containing gas, fluid or semi-fluid and not being created by puss accumulation” (Kramer 1974). Cysts are more common in the jawbone than in any other bone. Depending on the epithelial origin, jaw cysts are divided into **odontogenic** and **non-odontogenic cysts**.

The epithelial lining of odontogenic cysts is derived from the epithelial remnants of tooth-forming organs and these cysts are further divided into developmental and inflammatory cysts. Odontogenic developmental cysts are of unknown origin and inflammatory cysts, like their name suggests, result from inflammation. **Developmental cysts** include “gingival cysts” of infants (Epstein pearls), odontogenic keratocysts, dentigerous (follicular) cysts, eruption cysts, lateral periodontal cysts, gingival cysts of adults and glandular odontogenic cysts (sialo-odontogenic cysts). **Inflammatory cysts** include radicular cysts (apical and lateral, and residual cysts) and paradental cysts. Odontogenic cysts comprise 90 % of the jaw cysts. (Kramer *et al* 1992, Neville *et al* 2002).

### 2.3.1. Radicular cyst (RC, Periapical cyst, Apical periodontal cyst)

Radicular cysts (RCs) are the most common odontogenic cysts (60-75%). RC originate from the epithelial rests of Malassez entrapped within chronic apical periodontitis. When small they are usually symptomless but may expand the bone while growing. Eventually, the cyst may perforate the cortex but frequently they do not grow to large dimensions. In an X-ray, RC shows a variable size of radiolucency with a loss of lamina dura, but the radiographic examination is not a diagnostic criteria.

In RC, non-keratinised stratified squamous epithelium partly or wholly surrounds the chronically inflamed granulation tissue capsule. Epithelial hyperplasia is often present and the epithelium may demonstrate spongiosis. The cyst lumen is filled with fluid and cellular debris. Sometimes the epithelium may include calcifications known as Rushton bodies. Both the cyst lumen and wall may present dystrophic calcifications, cholesterol clefts with multinucleated foreign body giant cells, red blood cells and hemosiderin pigmentation. The fibrous connective tissue wall of the cyst often demonstrates inflammatory infiltrate with lymphocytes, PMN cells, plasma cells, histiocytes, and rarely mast cells and eosinophils. Plasma cells often predominate the infiltration. The cyst wall occasionally contains hyaline bodies – scattered, circumscribed corrugated, condensed collagenous rings containing eosinophilic material - surrounded frequently by multinucleated giant cells and lymphocytes. The eosinophilic material may contain various cells and it may undergo dystrophic calcification. These bodies can be seen in any intraosseous chronic inflammation and they represent inflammatory exudate pools (*i.e.* extravasated serum) that with time undergo fibrosis and occasionally dystrophic calcification. The multinucleated foreign body giant cells appear at the site to remove the debris. The cyst wall becomes more fibrotic with diminishing vascularity and inflammatory infiltration. (Neville *et al* 2002).

The RCs tend to expand, “balloon-like”, in all directions equally, and the surrounding bone is resorbed, mainly by osteoclast function (Formigli *et al* 1995). Cyst lining cell cultures have been demonstrated to release osteoclast stimulating bone resorbing factors, prostaglandins, mainly from cyst capsule fibroblasts, and immunoglobulins are secreted by plasma cells (Formigli *et al* 1995, Meghji *et al* 1996, Takahashi *et al* 1996). Interleukins and other cytokines are secreted from monocyte/macrophage-like cells, epithelial cells and other cells to stimulate bone resorption (Bando *et al* 1993). IL-1 $\alpha$ , IL-1 $\beta$ , IL-4, IL-6, IL-10 and IFN- $\gamma$  are detected in RC fluid and explant media, IL-1 $\beta$  being characteristics of RCs in comparison to FC and KC (Hoenig *et al*

1991, Formigli *et al* 1995, Meghji *et al* 1996, Walker *et al* 2000). Cytokines are able to trigger cells in RC to produce proteolytic enzymes, such as IL-1 $\alpha$  which enhances gelatinase-A and -B (MMP-2 and MMP-9) production in explant culture (Kubota *et al* 2000). MMP-1 (collagenase – 1) protein has been found in subepithelial fibroblasts and epithelial cells of RC (Lin *et al* 1997). Collagenases (MMP-1 and MMP-8) and gelatinases (MMP-2 and MMP-9) have been detected in cyst fluid and cyst wall extracts (Teronen *et al* 1995a, b, Kubota *et al* 2000). Bacterial endotoxins, always present in RC, stimulate keratinocyte proliferation, and bacterial products activate MMP production (Ding *et al* 1995, 1996, Meghji *et al* 1996). These proteolytic enzyme cascades are most likely involved in the bone matrix degradation, BM and epithelial cell processing during cyst expansion.

### **2.3.2. Follicular cyst (FC, Dentigerous cyst)**

Follicular cysts are next to RCs the most common of odontogenic cysts (10-15%). A FC originates from the reduced enamel epithelium derived from the enamel organ. It encloses partly or totally the crown of an unerupted tooth and it is attached to the tooth at the cemento-enamel junction. FCs most frequently surround mandibular third molars, followed by maxillary permanent canines, maxillary third molars and mandibular second premolars. FCs are usually symptomless, but they may grow to a remarkable size expanding the bone in the involved area. Usually they do not show any pain unless secondary inflammation is present. Radiologically, FCs usually show unilocular radiolucency attached to an unerupted tooth. (Neville *et al* 2002).

The cyst epithelium is usually two to five layers thick. It consists of non-keratinised cells and the interface to connective tissue is flat. If inflammation is present, the epithelium may show varying amounts of hyperplasia with development of rete ridges. Focal areas of mucous cells (goblet cells) may be seen in the epithelial lining, and rarely ciliated columnar or sebaceous cells. The connective tissue wall is loosely arranged having sometimes cholesterol clefts and islands of odontogenic epithelium present. When inflammation is present, the collagen amount in the cyst wall increases with variable infiltration of inflammatory cells. The cyst contains a proteinaceous, yellowish fluid frequently with cholesterol crystals. (Neville *et al* 2002).

The developing stimulus of a FC is unknown and the cyst formation mechanism is still unclear. The expansion mechanism of a FC is, anyhow, probably similar to that of a RC but is dependent on bone destruction and osmotic pressure (Neville *et al* 2002). The triggering mechanism in FCs for the release of bone resorbing factors from the cyst cells may differ from RCs, because inflammation is not necessarily always present. Bone resorption stimulating factors, including growth factors and cytokines, are present in a FC wall and epithelium (Meghji *et al* 1996, Li *et al* 1997). These stimuli are able to release MMPs, like gelatinases, from cyst cells (Kubota *et al* 2000). Collagenases and gelatinases are found in FC wall extracts (Teronen *et al* 1995a, b) suggesting that these enzymes take part in the FC expansion as well.

### **2.3.3. Odontogenic keratocyst (KC, Primordial cyst)**

Odontogenic keratocyst is the third most common of odontogenic cysts (5-10%). It is thought to originate from the cell rests after the dissolution of the dental lamina. Most of the KC cases occur in ages 10 to 40 with a slight male predilection and 70-80 % occur in the mandible, most often in third molar region and ascending ramus. In maxilla it most often involves the region posterior to the first premolar. The expansion mechanism of KCs differs from RCs' and FCs' unicentric pattern. An odontogenic keratocyst tends to grow in an antero-posterior direction often not showing bone expansion. KCs may, however, cause swelling and pain. Radiologically, KCs demonstrate a well-defined radiolucent uni- or multilocular area with smooth and often corticated

margins. An unerupted tooth is involved in 25-40 % of the cases. The diagnosis of KC is based on histopathology, radiologic findings being only suggestive. The recurrence rate of KCs is high varying from 3 to 60 %. Recurrence takes place more often in mandibular KC, especially in the posterior body and ascending ramus. (Myoung *et al* 2001, Neville *et al* 2002). Although the majority of KCs appear as solitary lesions, multiple KCs may be present and they are associated with nevoid basal cell carcinoma (Gorlin-Goltz) syndrome (Myoung *et al* 2001, Neville *et al* 2002).

The histopathology of a KC often shows a thin friable, folded wall, which is difficult to enucleate in one piece. The cyst wall capsule may contain epithelial rests giving the basis to independent satellite cysts (daughter cysts) around the main lesion. KC lumen may contain liquid material similar to a serum transudate, but often it contains thick cheesy material composed of keratinaceous debris having a low soluble protein level. (Neville *et al* 2002). The epithelial lining surrounded by the fibrous cyst capsule is usually composed of six to eight cell layers thick squamous epithelium. The uniform thick, often corrugated epithelial surface shows parakeratotic epithelial cells but areas of orthokeratosis may be present. The well-defined basal cell layer consists of palisaded columnar or cuboidal cells, which are often hyperchromatic. When inflammatory changes are present the epithelial lining may lose its keratinization and histological characteristics of its basal cell layer and also rete ridge formation may be seen. The epithelium easily detaches from the cyst stroma, a phenomenon that may increase the recurrence rate of KCs. The orthokeratinized variant (orthokeratinized odontogenic cyst) of the KC is not associated with Gorlin-Goltz syndrome and the recurrence rate is much lower, though it has been suggested that this orthokeratinized type might have a greater risk for malignancy. The orthokeratinized epithelium has a granular layer and the basal layer is poorly organized. Radiographically and clinically 2/3 of the orthokeratinized odontogenic cysts show similarities with the follicular cyst; most often involving an impacted third lower molar. It is suggested that the orthokeratinized odontogenic cyst should be categorized differently from KCs. (Neville *et al* 2002, Regezi 2002).

The growth and enlargement of KCs has often been regarded as evidence of their neoplastic behaviour (Myoung *et al* 2001, Shear 2002a). Possible inflammation has little effect on the KC growth. The latest point based on the multilocular and loculated outlines of the KC is that the enlargement of a KC appears in a multicentric growth pattern with proliferation of local groups of epithelial cells against the semi-solid cyst contents. The intrinsic growth potential and infolding of the epithelium into the cyst wall during the KCs multiphase growing indicate active epithelial proliferation and support the suggestion that KC may more likely present a benign neoplasm than a cyst (Shear 2002a, c). The finding that KC epithelial cells overexpress p53, a protein usually overexpressed in malignant lesions but not in normal cells, further strengthens the notion of KCs' potential neoplastic nature (Piattelli *et al* 2001). A mutation in the p53 gene may be a reason for the increased cell proliferation. The p53+ basal cells are found more often in KCs with epithelial dysplasia and the p53+ epithelium is usually parakeratotic (Piattelli *et al* 2001). The proliferating cell nuclear antigen (PCNA), indicating active proliferation in p53+ cells, is also found more often in KCs than other odontogenic cysts (Li *et al* 1994, Piattelli *et al* 2001, Shear 2002b). It has been shown that the KC epithelium has higher mitotic activity than FC or RC epithelia, and the mitotic activity is often found in basal or suprabasal cells (Matthews *et al* 1988, Li *et al* 1994). The dissolution of bone matrix by the cyst wall is mediated by osteoclasts, evidently in concert with the biologically active proteases, including MMPs (Neville *et al* 2002). Different cytokines and other cell mediators, produced in a KC as well, can stimulate the protease production or activation by KC cells. KC epithelial cells can further express TGF- $\alpha$ , IL-1 $\alpha$ , IL-6 and proMMP-9 (Meghji *et al* 1992, 1996, Li *et al* 1997, Kubota *et al* 2000). IL-1 is able to enhance MT1-MMP expression in KC fibroblasts and increases both proMMP-2 and proMMP-9 activation (Kubota *et*

*al* 2000, 2002). Active interstitial collagenases (MMP-1 and MMP-8) and gelatinases (MMP-2 and MMP-9) have been found in the cyst extracts and fluids (Ylipaavalniemi 1978, Teronen *et al* 1995a, b, Sorsa *et al* 1988, Kubota *et al* 2000).

The reasons for KCs' special characteristics, epithelial detachment and growth potential, are not yet completely clarified and require further studies.

## 2.4 Plasma cells

Plasma cells accumulate in chronic inflammation and by tradition their role is to act in the humoral immune response by secreting antibodies. They derive from B lymphocytes and their differentiation requires multiple stimuli. The primary stimulus is antigen interaction with surface immunoglobulins (IgM and IgG) of B lymphocyte. The activated B lymphocyte "presents" the antigen to T-helper lymphocytes that in turn secrete distinct growth and differentiation factors. These molecules, particularly IL-4 and IL-5, secreted by T-helper cells, induce B cell differentiation. The final differentiation requires an additional B cell differentiation factor, IL-6 secreted by many lymphoid and nonlymphoid cells, to be present (Nisengard and Newman 1994). Also other cytokines, IL-3 and IL-10, with T cell induction may activate the B cell differentiation into plasma cells (Merville *et al* 1995, Rousset *et al* 1995).

The main function of plasma cells is to secrete immunoglobulins, antibodies taking part in the host defence system, by binding to antigens. Antibody secretion is the basis of humoral immunity. Antibodies are active against bacteria, viruses and tumours, and they are able to neutralize a number of microbial products, particularly toxins, which can be harmful to the host tissues. Immunoglobulins are glycoproteins containing a basic monomeric structure consisting of two heavy and two light chains. Based on differences in the H chain region, immunoglobulins are divided to five main groups: IgM, IgG, IgA, IgD and IgE, and based on L chain dissimilarities to  $\kappa$  and  $\lambda$  subgroups. Plasma cells produce immunoglobulins and antibodies against foreign antigens, but they are also known to produce and secrete antibodies against self antigens leading to autoimmune diseases (Andrew *et al* 1991), and also certain cytokines (IL-10, TGF- $\beta_1$ , TNF- $\alpha$ ) (Matthes *et al* 1995, DiGirolamo *et al* 1997). Plasma cells, specially myeloma cells, and B lymphocytes also secrete certain matrix metalloproteinases (MMP-2, MMP-3 and MMP-9) and their inhibitors (TIMP-1) (Stetler-Stevenson *et al* 1997, DiGirolamo *et al* 1998).

### 2.4.1 Multiple myeloma (MM) and plasmacytoma (PLC)

Multiple myeloma is the most common plasma cell malignancy. It generally occurs as a disseminated lesion involving many bones (**multiple myeloma**) or seldom as a solitary bone/soft tissue lesion (solitary myeloma or **plasmacytoma/extramedullary plasmacytoma**). Plasmacytoma may lead to multiple myeloma. MM is a progressive and fatal malignancy of plasma cells. It may involve IgA, IgD or IgE but most frequently involving IgG producing monoclonal plasma cells. In MM abnormally high levels of the immunoglobulin or its polypeptide chains are secreted into the serum and urine. Most often MM appears in patients between 50 and 70 years affecting men more often than women. The skull, vertebrae, sternum, ribs and pelvic bones are commonly affected though lesions in jaws are not uncommon (30% of the cases). Jaw lesions appear more commonly in the posterior region of the mandible. The bone lesions present unbalanced bone remodelling: excessive resorption with low bone formation. (Neville *et al* 2002).

The most characteristic of the clinical symptoms of MM is bone pain and some patients may present pathologic fractures caused by bone destruction. Patients may suffer from anaemia and fever may be present as a result of neutropenia. Metastatic calcifications may occur in soft tissues due to hypercalcemia caused by osteolysis. The excess of produced light chains, unattached to heavy chains are excreted to the urine and often precipitate in renal tubules, and may cause renal failure. This light chain protein found in the urine is called Bence-Jones protein. Amyloidosis may appear even as an initial manifestation of the disease. This deposition of extracellular proteinaceous substance, amyloid, often affects the eyelid region, and when present in the tongue may lead to macroglossia. Radiographically MM appears as sharply demarcated radiolucencies or ragged radiolucent areas often well evidenced in skull radiographs. Histologically these lesions show dense cellularity with little or no supporting stroma. The lesions consist of variably differentiated, plasmacytoid cells invading and replacing the normal host tissue. Occasionally homogenous, relatively acellular amyloid material may be present among neoplastic cells. (Neville *et al* 2002). The criteria to diagnose MM are seen in the Table 1.

**Table 1. Diagnostic criteria for plasma cell myeloma**

(Modified from WHO criteria; edited by Jaffe *et al* 2001)

The myeloma diagnosis requires a minimum of one major or three minor criteria which must include (1) and (2). These criteria must be manifest in a symptomatic patient with progressive disease.

Major criteria: 1. Marrow plasmacytosis (>30%)

2. Plasmacytoma on biopsy

3. M-component: Serum IgG > 3.5g/dl, IgA >2g/dl  
Urine >1g/24hr of Bence-Jones (BJ) protein

Minor criteria: 1. Marrow plasmacytosis (10-30%)

2. M-component: present but less than above

3. Lytic bone lesions

4. Reduced normal immunoglobulins (<50% normal):

IgG <600mg/dl, IgA <100mg/dl, IgM <50mg/dl

In addition to immunoglobulin secretion, the plasma cells in MM excrete many different cytokines and MMPs. IL-6 has been widely studied and its expression by malignant plasma cells is related to MM invasiveness (Pattengale 1997, Sati *et al* 1998). IL-6, not expressed in normal plasma cells, is essential for the growth of MM, by inducing the differentiation of plasmablasts into mature malignant plasma cells (Lauta 2001), and for the survival of myeloma cells by preventing spontaneous apoptosis (Pattengale 1997). Myeloma cells, in addition to secreting IL-6, also stimulate stromal and bone marrow cells to release large amounts of IL-6 via an IL-1 dependent pathway (Carter *et al* 1990). Cytokines are able to provoke IL-6 production in bone marrow-derived stromal cells and cytokines provoke MMP production and secretion by many cells, though IL-6 has not been found to interfere with MMP production in MM lesions (Carter *et al* 1990, Barille *et al* 1997, Vacca *et al* 1999). The MM plasma cells interfere with the invasive potential of MMs also by secreting fibroblasts growth factor (FGF-2), a potent angiogenic factor, to increase angiogenesis (Vacca *et al* 1999). MM cells can produce gelatinases (MMP-2 and MMP-9), and upregulate collagenase-1 (MMP-1) expression and induce MMP-2 activation in bone marrow stromal cells of MM patients (Barille *et al* 1997, Vacca *et al* 1999, Ria *et al* 2002).

MMPs (MMP-1, MMP-2, MMP-9) expression of MM cells is known to increase during the active phase of the disease (Barrille *et al* 1997, Vacca *et al* 1999). The ECM proteins fibronectin (FN) and vitronectin (VN) are known to enhance MM plasma cell proliferation and gelatinase (MMP-2 and MMP-9) release from MM cells via  $\alpha_v\beta_3$  integrin pathway (Ria *et al* 2002).

## 2.5 Laminin-5 (Ln-5)

Laminins are a family of non-collagenous BM proteins that appear in several isoforms each presenting a unique combination of  $\alpha$ ,  $\beta$  and  $\gamma$  chain linked together with disulfide bonds. In addition to acting as structural components, laminins are involved in the cell differentiation, adhesion and migration. (Lohi 2001).

Ln-5, previously called kalinin, nicein or epiligrin, functions as an anchoring filament component between epithelial cells and the BM. Keratinocytes synthesize Ln-5 (Amano *et al* 2001) and it consists of  $\alpha_3$ :  $\beta_3$ :  $\gamma_2$  subunits of which the  $\gamma_2$  chain is unique for Ln-5 (Kallunki *et al* 1992). Ln-5 has an ambiguous role both in promoting cell adhesion and migration and its overexpression in tissues is closely related to malignancy (Soini *et al* 1996, Lohi 2001, Patel *et al* 2002). The cell adhesive function of intact Ln-5 is mediated through  $\alpha_3\beta_1$  and  $\alpha_6\beta_4$  integrins being connected to type VII collagen in the BM (Rousselle *et al* 1997). The  $\gamma_2$  chain does not contribute to the adhesive quality of Ln-5, but plays a crucial role in the regulation of cell migration (Salo *et al* 1999). The specific cleavage of a  $\gamma_2$  chain to a 80 kDa form has been reported to cause epithelial cell migration and is connected to cell invasiveness (Giannelli *et al* 1997, Skyldberg *et al* 1999, Gilles *et al* 2001). MMP-2, -3, -13, -14, -20 and MT1-MMP are among the MMPs able to cleave Ln-5 at a special site in order to promote epithelial cell motility (Giannelli *et al* 1997, 1999, Koshikawa *et al* 2000, Gilles *et al* 2001, Pirilä *et al* 2001b, 2003). These findings suggest that a fragmented laminin  $\gamma_2$  chain has a specific role in the regulation of the epithelial cell migration.

## 2.6 Matrix metalloproteinases (MMPs)

Matrix metalloproteinases form a structurally related group of at least 25 (22 human homologues)  $\text{Ca}^{2+}$ - and  $\text{Zn}^{2+}$ -dependent endopeptidases collectively capable of degrading practically all ECM and BM components. In addition, MMPs can modulate many other substrates including ILs and other cytokines, serine proteinase inhibitors (serpins), growth factors and chemokines (Uitto *et al* 2003). MMPs are divided into six subgroups: collagenases, gelatinases, membrane-type MMPs (MT-MMPs), stromelysins, matrilysins and other MMPs (Fig. 3 and Table 2). They have a role in many normal physiological events, like ovulation, embryo implantation, organ development, angiogenesis, wound healing and bone remodelling. Normal embryonic development and tissue remodelling needs a controlled balance between ECM synthesis and degradation, as well as a balance between MMPs and their natural inhibitors TIMPs. Overproduction of MMPs occurs in many tissue destructive pathological conditions and MMPs are known to influence many chronic tissue destructive inflammatory and autoimmune diseases, like rheumatoid arthritis, osteoarthritis, periodontitis, blistering disorders of the skin, lung diseases, eye diseases and chronic ulcerations. They also affect tumour growth, invasion and metastasis. In the inflammatory process, MMPs, being upregulated by cytokines and other proinflammatory mediators, are mainly responsible for the ECM and BM degradation. (Kähäri and Saarialho-Kere 1999, Johansson *et al* 2000). MMPs are active in physiological and pathological bone remodelling being expressed by osteoblasts and osteoclasts (Rifas *et al* 1989, Meikle *et al* 1992, Vaes *et al* 1992, Reponen *et al* 1994, Wucherpennig *et al* 1994).

In addition to tissue remodelling, MMPs participate in many other cellular functions (Vu and Werb 2000). They adapt cellular behaviour, for example, by inducing cell migration in normal growth and tissue remodelling, such as wound healing, angiogenesis, as well as in tumour invasion and metastasis (Curran and Murray 2000, Johansson *et al* 2000, Vu and Werb 2000, Vihinen and Kähäri 2002). Molecules affecting cellular functions can be modified by MMPs; the precursor of IL-1 $\beta$  can be activated by MMP-2, MMP-3 and MMP-9, although excess or prolonged incubation with MMPs can also result in IL-1 $\beta$  inactivation (Ito *et al* 1996, Schönbeck *et al* 1998).

Extracellular matrices themselves adjust to the cellular functions, like growth, cell shape changes, migration and differentiation, for example, by controlling cellular adhesion. An ECM influences cell behaviour by maintaining signal molecules, such as growth-factors and growth-factor binding proteins, and acting as a ligand for cellular receptors, including integrins, that can transduce signals to the cell interior. MMPs may cleave the ECM and release bioactive cell surface molecules or regulate the growth-factor availability by cleaving the ECM proteins that can bind to them (Uitto *et al* 2003). Various MMPs can degrade decorin, a collagen-associated small protein that binds to TGF- $\beta$ , and may as a "secondary effect" release TGF- $\beta$  to carry out its biological functions. On the other hand, the release of TGF- $\beta$  may have a negative feedback on MMP production. (Sternlicht and Werb 2001, Uitto *et al* 2003).

MMPs modulate the activity of other proteinases by activating latent enzymes or inactivating their inhibitors. MMP-3 can cleave the urokinase type plasminogen activator and MMP-1 and MMP-8 are able to cleave the  $\alpha_1$ -proteinase inhibitor and  $\alpha_1$ -antichymotrypsin (Michaelis *et al* 1990, Vu and Werb 2000). MMPs are also able to activate each other in a complicated cascade network. MMP-2 and MT1-MMP, for example, are able to activate latent MMP-13, and MT1-MMP activates MMP-8, as well as the active form of MMP-2 together with MMP-13 activate MMP-9 (Knäuper *et al* 1996a, Cowell *et al* 1998, Saarialho-Kere 2000, Holopainen *et al* 2003). MMPs' behaviour in tissues is multivariate and many questions are still unanswered (Uitto *et al* 2003). MMPs share significant structural similarities; all of them contain the N-terminal signal sequence ("pre"domain) followed by the "pro"domain that maintains enzyme latency usually until removed, and the zinc-binding catalytic domain. With three exceptions (MMP-7, MMP-23 and MMP-26) the hemopexin/vitronectin domain is connected to the catalytic domain. The hemopexin domain participates in the catalytic activities and it can bind to TIMP and certain substrates (Sternlicht and Werb 2001). MT-MMPs contain a transmembrane domain and a short cytoplasmic C-terminal tail (Fig. 3).

### 2.6.1 Collagenases (MMP-1, MMP-8, MMP-13)


The human interstitial collagenase subfamily contains three members: MMP-1 (fibroblast type collagenase, collagenase-1), MMP-8 (neutrophil collagenase, collagenase-2) and MMP-13 (collagenase-3). In addition to these human collagenases, a collagenase, MMP-18, has been found and cloned only from *Xenopus laevis* (Stolow *et al* 1996). The mammalian analogous has not yet been found.

Collagenases cleave the native fibrillar collagen types I-III to generate  $\frac{3}{4}$ - and  $\frac{1}{4}$ -fragments. The cleavage takes place in a specific site between the glycine-isoleucine (Gly-Ile) of the  $\alpha_1$  chain and the glycine-leucine (Gly-Leu) residues of the  $\alpha_2$  chain forming triple helical fragments that in body temperature denature into randomly coiled gelatin, being further degraded by other gelatinolytic MMPs and proteinases (Birkedal-Hansen *et al* 1993, Sternlicht and Werb 2001). The collagenases differ in their substrate specificities and functional roles. MMP-1 preferably

**Figure 3. MMP structure** (Modified from Sternlich and Werb 2001)


Pre: Pre domain, Pro: propeptide with ZN-binding thiol group (SH), Fu: furin site, ZN: Zn-binding site, F: fibronectin type II insert, H: Hinge region, TM: transmembrane domain, C: cytoplasmic tail, C/P:cysteine/proline, IL-1R: interleukin-1 receptor.

**1) Minimal Domain MMPs**



MMP-7: matrilysin, MMP-26: endometase

**2) Simple Hemopexin Domain-Containing MMPs**




MMP-1: collagenase-1, MMP-8: collagenase-2, MMP-13: collagenase-3, MMP-18: collagenase-4, MMP-3: stromelysin-1, MMP10: stromelysin-2, MMP-27, MMP-12: metalloelastase, MMP-19: RASI-1, MMP-20: enamelysin, MMP-22: CMMP

**3) Gelatin-binding MMPs**




MMP-2: gelatinase-A, MMP-9: gelatinase-B

**4) Furin activated Secreted MMPs**



MMP-11: stromelysin -3, MMP-28: epilysin


**5) Transmembrane MMPs**



MMP-14: MT1-MMP, MMP-15: MT2-MMP, MMP-16: MT3-MMP, MMP-24: MT5-MMP


**6) GPI-linked MMPs**

(glycophosphatidyl 1 inositol-anchoring domain)




MMP-17: MT4-MMP, MMP-25: MT6-MMP

**7) Vitronectin-like MMPs** MMP-21: XMMP



**8) Cysteine/Proline-rich IL-1 Receptor-like Domain MMPs** MMP-23



degrades collagen III, MMP-8 prefers type I collagen (Birkedal-Hansen *et al* 1993), and MMP-13 collagen II (Knäuper *et al* 1996a) (Table 2).

Human **MMP-1** was first cloned and sequenced from skin fibroblasts (Goldberg *et al* 1986). Since then it has been found to be produced by keratinocytes, endothelial cells, monocytes and macrophages, chondrocytes, osteoblasts and various tumour cells (Meikle *et al* 1992, Birkedal-Hansen *et al* 1993, Giambernardi *et al* 1998). MMP-1 is produced on demand by transcriptional initiation and the delay after the trigger mechanism can be up to 12 hours (Birkedal-Hansen *et al* 1993). It is produced as glycosylated proenzymes 52 kDa and 57 kDa in size, and upon activation (*i.e.* propeptide cleavage or removal) converted to the active size of 42 kDa and 47 kDa respectively. MMP-1 cleaves several ECM components but is ineffective against most BM components. It has been connected to many physiological phenomena, like embryonic development and the migration of keratinocytes during wound healing, as well as to the growth of malignant tumours (Saarialho-Kere *et al* 1992, 1995, Vaalamo *et al* 1997, Giambernardi *et al* 1998, Vu and Werb 2000).

**MMP-8** is synthesized and stored in PMN cells during their maturation in bone marrow and released upon PMN degranulation induced by various extracellular stimuli, like cytokines or bacterial contact (Ding *et al* 1995, 1996, 1997). In addition inducible *de novo* MMP-8 expression has been found to be expressed by chondrocytes, fibroblast-like cells, monocytes, epithelial cells and keratinocytes, as well as melanoma cells and oral cancer cells (Hanemaaijer *et al* 1997, Giambernardi *et al* 1998, Bachmeier *et al* 2000, Tervahartiala *et al* 2000, Prikk *et al* 2001, 2002, Moilanen *et al* 2002). MMP-8 is secreted either as a 55 kDa unglycosylated form or a 75 kDa glycosylated form and after activation its molecular size usually decreases by 10-20 kDa (Hasty *et al* 1990, Ding *et al* 1995, Hanemaaijer *et al* 1997, Moilanen *et al* 2003). The main substrates for MMP-8 are fibrillar collagens (Birkedal-Hansen *et al* 1993). MMP-8 is catalytically more effective in cleaving substrates (except collagen III) than MMP-1. Increased MMP-8 levels are detected in many inflammatory diseases like rheumatoid arthritis, chronic lung inflammations and periodontitis (Konttinen *et al* 1991, Sorsa *et al* 1994, 1999, Ingman *et al* 1996, Uitto *et al* 1998, Tervahartiala *et al* 2000, Mäntylä *et al* 2000, 2003, Marchenko *et al* 2001a, b, Prikk *et al* 2001, 2002, Lanone *et al* 2002).

**MMP-13** has the widest substrate selection among the interstitial collagenases and, in addition to collagens, it is able to cleave various BM components. MMP-13 cleaves type II collagen more efficiently than type I and III and among interstitial collagenases, it is most effective in cleaving gelatin (Mitchell *et al* 1996, Lindy *et al* 1997). It is secreted as a 60 kDa glycoprotein and is converted to a 48 kDa form after activation. MMP-13 can be activated by other MMPs including MMP-2, MMP-3, MMP-10, MT1-MMP, MT2-MMP and serine proteases human trypsin-2 and plasmin (Knäuper *et al* 1996a, b, D'Ortho *et al* 1997). MMP-13 was first cloned from human breast cancer, indicating a role in malignancy (Freije *et al* 1994). The physiologic expression of MMP-13 seems to be limited only to developing bone (Stähle-Bäckdahl *et al* 1997) and wound healing (Ravanti *et al* 1999, Pirilä *et al* 2001b), but it is widely expressed in pathological conditions characterized by excessive ECM degradation including rheumatoid arthritis, osteoarthritis, periodontitis and chronic ulcerations (Lindy *et al* 1997, Vaalamo *et al* 1997, Uitto *et al* 1998, Johansson *et al* 2000, Tervahartiala *et al* 2000, Kiili *et al* 2002). MMP-13 is further expressed in skin and mucosal squamous cell carcinoma (SCC) cells, hypertrophic chondrocytes, osteoblasts, and many carcinoma and melanoma cells (Mitchell *et al* 1996, Johansson *et al* 1997a, b, Giambernardi *et al* 1998, Uria *et al* 1998, Bachmeier *et al* 2000, Hofmann *et al* 2000, Thomas *et al* 2000). Due to the relative wide substrate specificity, MMP-13 is regarded to be an all-round tool for malignant cells in growth and invasion (Kähäri and Saarialho-Kere 1999).

## 2.6.2 Gelatinases (type IV-collagenases, MMP-2, MMP-9)

The gelatinase subgroup contains two enzymes: gelatinase-A (MMP-2) and gelatinase-B (MMP-9). The substrate specificity and primary structure of gelatinases are rather similar (Fig. 3, Table 2). Within their catalytic domain, gelatinases have three head-to-tail cysteine-rich repeats that are required to bind and cleave especially the denatured collagen and elastin. These inserts resemble the collagen binding type II repeats of fibronectin.

**MMP-2** was first purified from a murine malignant melanoma tumour and found to be a potent BM type IV collagen degrading enzyme (Salo *et al* 1983). It is expressed in many different cell types including keratinocytes, fibroblasts, chondrocytes, monocytes, osteoblasts, endothelial cells, T-lymphocytes and malignant plasma cells, leukaemia, carcinoma and melanoma cells (Stetler-Stevenson 1990, Barille *et al* 1997, Giambernardi *et al* 1998, Sutinen 1998). PMNs do not express or contain MMP-2. The latent MMP-2 is secreted in a 72 kDa form and upon activation is converted to a 59-62 kDa form. Collagens (I, II, IV, V, VII, X, XI), gelatins and BM components are cleaved by MMP-2 (Aimes and Quiqley 1995, Konttinen *et al* 1998, Sternlicht and Werb 2001). MMP-2 is involved in many processes that require ECM remodelling and its overexpression is closely connected to cell migration and to the invasive and metastatic potential of malignant tumours (Stetler-Stevenson 1990, Autio-Harmanen *et al* 1992, Tryggvason *et al* 1993, Soini *et al* 1994, Mäkelä *et al* 1999, Pirilä *et al* 2001b, Vihinen and Kähäri 2002).

**MMP-9** was originally identified from human macrophages (Vartio *et al* 1982) but is produced by PMNs, keratinocytes, T-lymphocytes, monocytes, plasma cells and many transformed and malignant cells (Wucherpfennig *et al* 1994, DiGirolamo *et al* 1998, Giambernardi *et al* 1998). The substrate specificity of MMP-9 is similar to MMP-2, though it does not degrade type I-III collagens as widely as MMP-2. MMP-9 plays an essential role in the resorption of collagen during bone remodelling and development (Meikle *et al* 1992, Vaes *et al* 1992, Wucherpfennig *et al* 1994) and its overexpression is also connected to the inflammatory reaction in lung and periodontal diseases (Westerlund *et al* 1996, Mautino *et al* 1997, Hoshino *et al* 1998, Atkinson and Senior 2003). Tumour cells and their metastatic potential, as well as cell invasion, are also linked to MMP-9 (Stetler-Stevenson 1990, Giambernardi *et al* 1998, Hofmann *et al* 2000, Thomas *et al* 2001, Vihinen and Kähäri 2002). The MMP-9 level is elevated in chronic wounds (Mirastschijski *et al* 2002, Peled *et al* 2002).

## 2.7 Regulation of MMPs

### 2.7.1 Transcriptional regulation of MMP expression

MMPs are expressed at a low rate in normal tissues but on demand their production and activation can be promptly induced. MMP-8 and MMP-9 are stored in PMN subcellular granules for a rapid release called selective degranulation, and MMP-7 storage in secretory epithelial cells in exocrine glands is an exception to this inductive *de novo* production (Johansson *et al* 2000). MMP expression is regulated at the transcriptional level by many growth factors and cytokines, oncogenes, hormones, ECM components and various cell-to-cell interactions. The stimulation of MMP expression by many growth factors and cytokines usually involves the activation protein-1 (AP-1) pathway. The extracellular stimulus activates the AP-1 transcription factor complexes to bind into the AP-1-binding site in the MMP gene stimulating MMP expression. AP-1 transcription factors regulate gene expression not only involved in development, differentiation

and proliferation, but also in stress reactions, inflammation and tumour progression (Angel and Karin 1991). The AP-1 binding site is often accompanied by another sequence called polyoma virus enhancer A binding protein 3 (PEA-3). The PEA binding site is activated in most MMP genes by oncogene-, growth factor- and phospholipase C-responsive elements (Gutman and Wasylyk 1990). Simultaneous activation of MMP-genes via the AP-1 and PEA sites is involved in the MMP regulation during tumour progression (Wernert *et al* 1992). The TGF- $\beta$  affects the transcription through a special mechanism that involves a TGF- $\beta$  inhibitory element (TIE) found in many MMP genes (Kerr *et al* 1990).

The influence of certain extracellular stimuli is variable depending on the stimulus, cell type and MMP gene in question. Many cytokines, like IL-1 and TNF- $\alpha$ , upregulate the inducible MMP production (MMP-1, MMP-3, MMP-7, MMP-8, MMP-9, MMP-13, and MMP-14) in many cell lines, while TGF- $\beta$ , glucocorticoids, IFN- $\gamma$  and retinoid acid have mainly suppressive effect. TGF- $\beta$  reduces MMP-9 production in fibroblasts (Overall *et al* 1991) and also blocks the induction of MMP-1 and MMP-3 while it induces the production of MMP-2, MMP-9 and MMP-13 in keratinocytes and MMP-7 in glioma cells (Salo *et al* 1991, Nakano *et al* 1993, Johansson *et al* 1997b). IL-1 $\beta$ , TGF- $\alpha$  and the epidermal growth factor (EGF) induce high-level MMP-3 expression in synovial fibroblasts, but MMP-10 expression is induced in keratinocytes (Birkedal-Hansen *et al* 1993). Some cell-to-cell adherence proteins, ECM proteins, bacterial cells and products and hormones may also stimulate the MMP production and secretion (Saarialho-Kere *et al* 1992, 1993, Ding *et al* 1996, 1997). The production of MMP-2 and MMP-14 is only moderately influenced by transcriptional regulation (Birkedal-Hansen *et al* 1993, Kähäri and Saarialho-Kere 1999). Overall, it is clear that the transcriptional regulation of MMP production is a very complicated phenomenon including the regulation of the production and degradation of transcription factors and the regulation of their trans-activating activities and via these processes modulate MMP production in cells.

### 2.7.2 MMP activation

MMPs are secreted in biologically latent proenzyme or zymogen forms that require activation to be catalytically competent in the extracellular milieu or at cell surfaces. The activation mechanisms *in vivo* are not yet completely understood and at least three different pathways have been described.


Cleavage by furin-like serine proteases can activate certain MMPs, like MMP-11, MMP-28 and MT-MMPs, intracellularly in the Golgi apparatus before secretion as an active enzymes (Pei and Weiss 1995). The proMMPs latency is maintained by a "cysteine switch", the interaction between cysteine residue and zinc ion. During activation the opening of the Cys-Zn<sup>2+</sup> bond allows Zn<sup>2+</sup> to react with H<sub>2</sub>O to maintain the stabilized open form of MMP, after which it still needs to pass through several structural changes to become fully active. Several chemical agents, like organomercurials, metal ions (Au<sup>2+</sup>, Hg<sup>2+</sup>), thiol reagents, detergents and oxidants can activate or induce the "cysteine switch" reaction by interacting directly with the Cys-residue. Certain proteinases, such as plasmin, chymotrypsin, cathepsin, trypsins, neutrophil elastase, kallikrein and mast cell tryptase, and also other MMPs, as well as bacterial and fungal proteases, can also induce the activation pathway by a series of successive and/or single cleavages (Sorsa *et al* 1992, 1997, Birkedal-Hansen *et al* 1993, Knäuper *et al* 1996b, Liu *et al* 2002, Moilanen *et al* 2003). MMP-9 has recently been detected to be active in binding to a substrate even in its proform, but still the activation needs the disengagement of the propeptide from the enzyme. This activation model is thought to take place via binding to a ligand or substrate (Bannikov *et al* 2002). In this

regard *in vivo* fully activated MMP-9 species with molecular size of 92 kDa have been detected in periodontitis-affected gingival crevicular fluid (GCF) (Westerlund *et al* 1996).

MMP-2, MMP-8 and MMP-13 can be activated by MT-MMPs (Deryugina *et al* 2001, Knäuper *et al* 1996b, Holopainen *et al* 2003). Activation of MMP-2 by MT1-MMP involves TIMPs. TIMP-2 binds to MT1-MMP and to proMMP-2 and another free TIMP-2 molecule is needed to mediate the cleavage and activation of bound MMP-2 by MT1-MMP (Deryugina *et al* 2001). Human MT2-MMP and MT4-MMP are unable to activate MMP-2 (Sternlicht and Werb 2001). The cell surface activation of MMP-13 by MT1-MMP can be direct or enhanced with proMMP-2 (Knäuper *et al* 1996b).

The activation of MMPs by each other is an intricate network (Fig. 4). MMP-3 is able to activate MMP-1, proMMP-2, MMP-8 and MMP-9. Active MMP-2 and MMP-13 can in collaboration activate proMMP-9, MMP-13 can be activated by MMP-2, MMP-3 and MMP-10. MT-MMPs can activate MMP-2, MMP-8 and MMP-13 (Knäuper *et al* 1996b, 1997, D'Ortho *et al* 1997, Cowell *et al* 1998, Curran and Murray 2000, Deryugina *et al* 2001, Holopainen *et al* 2003). MMP-7 can activate proMMP-8 and -9 (Balbin *et al* 1998, vonBredow *et al* 1998). However, since almost all human MMPs are expressed and secreted into an extracellular milieu in a latent proform, another type of protease is seemingly required to initially activate the first latent proMMP in the MMP activation network (Kähäri and Saarialho-Kere 1999, Uitto *et al* 2003). One potent candidate for such action is the tumour-associated trypsin-2 (TAT-2) (Sorsa *et al* 1997, Nyberg *et al* 2002, Moilanen *et al* 2003).

**Figure 4. MMPs activation network together with the initial activator TAT-2**  
(Modified from Ala-Aho 2002).



### 2.7.3 MMP inhibition

There are different mechanisms to inhibit or down-regulate MMPs. Inhibition may take place by interaction with an active  $Zn^{2+}$ -site or by cleaving the active enzyme or binding it to a non-active complex form. To influence the MMP levels it is also possible to down-regulate MMPs at the transcriptional level (Birkedal-Hansen *et al* 1993).

Tissue inhibitors of metalloproteinases (TIMPs) represent a multigene family with four members (Stetler-Stevenson *et al* 1989, Birkedal-Hansen *et al* 1993, Apte *et al* 1994, Leco *et al* 1994). They inhibit most MMP family members reversibly and the TIMPs are the major endogenous extracellular MMP regulators. Inhibition by TIMPs takes place via developing a MMP-TIMP complex or by inhibiting the activation of proMMPs (Goldberg *et al* 1989, Sorsa *et al* 1992, Birkedal-Hansen *et al* 1993). Different cells express TIMPs and they have been identified not only in tissues, but also in body fluids including gingival crevicular fluid (GCF) (Birkedal-Hansen *et al* 1993, Leco *et al* 1994, Sorsa *et al* 1994, Ingman *et al* 1996, Lin *et al* 2001). TIMP inhibition of MMPs is considered to exert a role in healing wounds, bone remodelling and tumour invasion (Edwards *et al* 1996, Vaalamo *et al* 1996, Sutinen *et al* 1998). Nonetheless, TIMP-3 is an exception, since it is mostly bound to ECM (Birkedal-Hansen *et al* 1993, Leco *et al* 1994). TIMP-2 has a special role in the regulation of MMP-2 activation by MT1-MMP on the cell membranes (Deryugina *et al* 2001). TIMPs also have growth-promoting properties (Hayakawa *et al* 1992, 1994). The delicate balance between TIMPs and MMPs evidently plays an important role in most normal tissue remodelling phenomena and in many tissue destructive inflammatory and malignant pathological conditions (Khokha *et al* 1989, Poulson *et al* 1992, Ingman *et al* 1996, Stetler-Stevenson *et al* 1997, Sutinen *et al* 1998, Soini *et al* 2001).

Serum  $\alpha_2$ -macroglobulin ( $\alpha_2M$ ) is a natural MMP inactivator and it entraps and bonds to the MMP after the enzyme has revealed the  $\alpha_2M$ -bait region. The trapping mechanism is irreversible but does not block the active site totally, so the enzyme is partly active for low molecular weight substrates. The  $\alpha_2M$ -proteinase combination is cleared from the circulation in the liver through uptake by special receptors (Birkedal-Hansen *et al* 1993).

Chelating agents, such as EDTA and 1,10-phenanthroline, bind to  $Zn^{2+}$  at the active site inhibiting MMPs non-selectively but are regarded as therapeutically useless (Birkedal-Hansen *et al* 1993). Bisphosphonates are a group of MMP inhibiting and down-regulating pharmacologic compounds which seemingly also act as chelating agents (Teronen *et al* 1997, 1999, Heikkilä *et al* 2002, 2003, Vihinen and Kähäri 2002).

Doxycycline and chemically modified non-antimicrobial tetracyclines (CMTs) inhibit MMPs by chelating and down-regulating their mRNA and protein expressions (Sorsa *et al* 1994, Golub *et al* 1995, Hanemaaijer *et al* 1997, Pirilä *et al* 2001ba). CMTs inhibit especially the pathologically elevated MMP-dependent periodontal soft tissue breakdown and bone destruction *in vivo* and *in vitro* (Golub *et al* 1995, 1998) and tumour cell proliferation and invasion (Lukkonen *et al* 2000, Gu *et al* 2001, Lokeshwar *et al* 2002). CMTs have also been tested in animals and shown to inhibit caries progression in tooth and tumour growth and metastasis as well as prevent inflammatory bone resorption (Golub *et al* 1998, Sulkala *et al* 2001, Bezerra *et al* 2002, Lokeshwar *et al* 2002). When combined with bisphosphonates, CMTs synergistically inhibit bacterial-produced periodontal soft and hard tissue breakdown (Llavaneras *et al* 1999, 2001). Peptidomimetic matrix metalloproteinase inhibitors (MMPI) mimic the structure of MMP substrates, as well as function as competitive inhibitors (Vihinen and Kähäri 2002). Batimastat is the first synthetic clinically tested MMP inhibitor interacting with  $Zn^{2+}$  in their catalytic site.

Animal model studies have shown the inhibition of tumour growth, metastasis, and of angiogenesis (Curran and Murray 2000). Marimastat is the second-generation synthetic wide spectrum MMP inhibitor that has been clinically evaluated as an anticancer agent (Curran and Murray 2000, Vihinen and Kähäri 2002). CTTHWGFTLC-peptide is a selective gelatinase (MMP-2 and MMP-9) inhibitor (Koivunen *et al* 1999, Pirilä *et al* 2001b, 2003)

**Table 2. Matrix metalloproteinases** (Modified from Sternlicht and Werb 2001)

<u>MMP</u>	<u>Enzyme</u>	<u>Substrates</u>
<b><u>Collagenases</u></b>		
MMP-1	collagenase-1	aggrecan, collagens I-III,VII,VIII,X,XI, entactin, FN, gelatin, IGFBPs, Ln-1, link protein, myelin basic, tenascin, $\alpha$ 1AC, $\alpha$ 2M, $\alpha$ 1PI, VN, casein, fibrin, fibrinogen, IL1 $\alpha$ , IL1 $\beta$ , proTNF $\alpha$
MMP-8	collagenase-2	aggrecan, collagen I-III, laminin-5, fibrinogen, substanceP, $\alpha$ 1PI, $\alpha$ 2M,
MMP-13	collagenase-3	aggrecan, collagens I-IV, VI, IX, X, XIV, fibrillin, FN, gelatin, Ln-1, -5, osteonectin, casein, factor XII, $\alpha$ 2M, fibrinogen
<b><u>Gelatinases</u></b>		
MMP-2	gelatinase-A	aggrecan, collagens I, III-V, VII, X, XI, decorin, elastin, entactin, fibrillin, FN, fibulins, gelatin, IGFBPs, Ln-1, -5, link protein, myelin basic, osteonectin, tenascin, VN, fibrin, $\alpha$ 1AC, $\alpha$ 1PI, fibrinogen, IL1 $\beta$ , proTGF $\beta$ , proTNF $\alpha$ , plasminogen, substanceP
MMP-9	gelatinase-B	aggrecan, collagens IV, V, XI, XIV, decorin, elastin, fibrillin, gelatin, Ln-1, link protein, myelin basic, osteonectin, tenascin, VN, $\alpha$ 2M, $\alpha$ 1PI, casein, fibrin, fibrinogen, IL1 $\beta$ , proTGF $\beta$ , proTNF $\alpha$ , plasminogen, substanceP
<b><u>Stromelysins</u></b>		
MMP-3	stromelysin-1	aggrecan, collagens III-V, VII, IX, X, XI, decorin, elastin, entactin, fibrillin, FN, gelatin, IGFBPs, Ln-1, link protein, myelin basic, osteonectin, tenascin, VN, $\alpha$ 1AC, $\alpha$ 2M, $\alpha$ 1PI, casein, fibrin, fibrinogen, IL1 $\beta$ , proTNF- $\alpha$ , plasminogen, substanceP, E-cadherin
MMP-10	stromelysin-2	aggrecan, collagens III-V, elastin, FN, gelatin, link protein, casein, fibrinogen
<b><u>Stromelysin like MMPs</u></b>		
MMP-11	stromelysin-3	IGFBPs, $\alpha$ 2M, $\alpha$ 1PI
MMP-12	metalloelastase	aggrecan, collagens I, IV, elastin, entactin, fibrillin, FN, gelatin, Ln-1, myelin basic, vitronectin, $\alpha$ 2M, $\alpha$ 1PI, factor XII, fibrinogen, proTNF- $\alpha$ , plasminogen
<b><u>Matrilysins</u></b>		
MMP-7	matrilysin	aggrecan, collagens I, IV, decorin, elastin, entactin, FN, fibulins, gelatin, Ln-1, link protein, myelin basic, osteonectin, tenascin, VN, $\alpha$ 1PI, casein, E-cadherin, fibrinogen, proTNF $\alpha$ , plasminogen
MMP-26	endometase, matrilysin-2	collagen IV, FN, gelatin, $\alpha$ 1PI, fibrinogen
<b><u>Transmembrane type MMPs</u></b>		
MMP-14	MT1-MMP	aggrecan, collagens I-III, entactin, fibrillin, FN, gelatin, Ln-1, -5, VN, $\alpha$ 2M, $\alpha$ 1PI, factor XII, fibrin, fibrinogen, proMMP2, proTNF- $\alpha$
MMP-15	MT2-MMP	aggrecan, entactin, FN, Ln-1, tenascin, proMMP2
MMP-16	MT3-MMP	collagen III, FN, proMMP2
MMP-24	MT5-MMP	
<b><u>GPI-type MMPs</u></b>		
MMP-17	MT4-MMP	fibrillin, FN, gelatin, proTNF $\alpha$
MMP-25	MT6-MMP	collagen IV, FN, gelatin, fibrin
<b><u>Other MMPs</u></b>		
MMP-18	collagenase-4 ( <i>Xenopus laevis</i> )	collagen I
MMP-19	RASI-1	collagens I, IV, FN, gelatin, tenascin, casein
MMP-20	enamelysin	amelogenin, aggrecan, Ln-5
MMP-23	CA-MMP	gelatin
MMP-28	epilysin	casein
MMP-21	XMMP	
MMP-22	CMMP	
MMP-27		

### 3. Aims and outlines of the study

#### 3.1 Aims of the study

The aims of this study were to gain a better understanding of the role of MMPs in the progression of inflammatory pulpal and periapical diseases, as well as, in the tissue destruction and enlargement of odontogenic cysts and PLC. In this study, I have concentrated on the *in vivo* presence of collagenases and gelatinases in pulp, periapical tissue, odontogenic cysts and PLC tissue, as well as on their regulation in cell cultures *in vitro*. I have also studied the changes in the collagenase levels during RTC in order to better understand the role of these enzymes in the healing process of periapical inflammatory changes.

#### 3.2 Outlines of the study

1. To determine the *in vitro* expression and regulation of collagenase-2 (MMP-8) in pulp cells and mature odontoblasts.
2. To study the presence, levels and molecular forms of MMP-8 in pulpal and periapical inflammation, and the changes in the concentrations, activation and molecular forms of MMP-8 in root-canal exudates during root-canal treatment.
3. To clarify the differences in the *in vivo* expression of Ln-5, collagenases (MMP-8 and MMP-13) and gelatinase (MMP-2) in different odontogenic jaw cysts and their possible role in the enlargement and tissue destruction caused by these cysts.
4. To study the expression of collagenases (MMP-8 and MMP-13) in plasma cells and in plasma cell diseases, such as MM and PLC, both *in vivo* and *in vitro* and their regulation by cytokines, such as IL-6 and TNF- $\alpha$ .

## **4. Materials and methods**

### **4.1 Patients and tissue samples**

#### **4.1.1 Pulp tissue and odontoblasts (I)**

All teeth (n=166) used for the experiments were freshly extracted caries-free third molars removed as part of the normal treatment at the Institute of Dentistry, University of Oulu, Oulu, Finland. After sterilizing the tooth and removing the soft tissue and cementum, the root was dissected gently close to the cemento-enamel junction. For culturing, the pulp was removed to a culture medium and the crowns with odontoblasts were placed in a sterile culture medium. For the native mRNA samples, the pulps were gently removed with forceps and placed into Eppendorf tubes. The odontoblasts lining the pulp chamber walls were immediately scraped off with a sterile excavator and stored at -70°C until analysed.

For immunohistochemistry, the enamel was cut off to prevent disturbances in sectioning the frozen samples. Immediately the enamel was removed with a thin diamond disc under water cooling, the teeth were immersed in liquid nitrogen and embedded, and serially cut into longitudinal sections on a piece of adhesive tape. The sections were air-dried and fixed in methanol, and air-dried again. Then the sections were demineralized and treated with bovine testicular hyaluronidase to overcome the masking effect of the matrix proteoglycans and then the procedure of immunohistochemical staining was carried out using Vectastain Elite Kit as explained later (Vector laboratories, Burlingame, CA, USA) (Table 3).

#### **4.1.2 Patients and diagnosis (II)**

10 patients suffering from CAP were selected for the study. The diagnosis was made by clinical, and mainly, by radiographic examination, showing the disappearance of the lamina dura and clear bone loss in the apical area. All the teeth included into the study were unvital and had only one root canal. No controls were used and the one patient excluded from the study had a root fracture. Root canal treatment was performed under sterile conditions in three visits (during two-week intervals) and the samples from the root canal exudates were collected from the root canals with sterile paper points during these visits. The pulpitis tissue specimens for immunohistochemistry were collected from patients with irreversible pulpitis when starting normal root treatment procedure under sterile conditions. Pulp tissue was gently removed with an excavator to an Eppendorf tube containing formalin.

Specimens from the patients were collected at a private dental clinic with the approval of the Ethical Committee of University of Helsinki, Faculty of Medicine, and with permission of the patients.

**Table 3. Tissue specimens**

<u>Material</u>	<u>Number of samples</u>	<u>fixation</u>	<u>publications</u>
Teeth 3rd molar	166	96% methanol (received fresh)	I
Pulpitis	10	10 % buffered formalin	II
Periapical periodontitis	10	10 % buffered formalin	II, IV
Radicular cysts	11 (10)	10% buffered formalin	III (IV)
Follicular cysts	11 (10)	10 % buffered formalin	III (IV)
Odontogenic keratocysts	16 (7)	10 % buffered formalin	III (IV)
Plasmacytoma	14	10% buffered formalin	IV

#### 4.1.3 Tissue specimens (II, III and IV)

Formalin-fixed and paraffin-embedded samples of chronic apical periodontitis, jaw cysts (RCs, FCs and KCs) and PLC, diagnosed histologically according to WHO criteria (Kramer *et al* 1992, Jaffe *et al* 2001), were used for immunohistochemistry and *in situ* hybridization (Table 3). These tissue specimens were randomly selected from the files of the Department of Oral Pathology, Institute of Dentistry, University of Helsinki, Helsinki, Finland, and from the files of the Department of Pathology, University of Oulu, Oulu, Finland.

## 4.2 Cells and culture methods

### 4.2.1. Odontoblasts and pulpal cells (I)

#### 4.2.1.1 Odontoblast cultures (I)

The odontoblast culture methods have been described in detail by Tjäderhane *et al* 1998. For odontoblast organ cultures 1.5% (w/v) agarose gel (Agarose NA, Pharmacia Biotech AB, Uppsala, Sweden) was mixed into the culture medium (OPTI-MEM I Reduced serum medium with antimicrobial element) and was used as embedding material for odontoblast cultures. The crowns with odontoblasts lining the pulpal chambers were partially embedded in the agarose gel. The pulp chambers were gently washed with culture medium to remove the pulp tissue fluid, and

finally filled with the culture medium. The crowns were covered with glass cover slips to prevent evaporation from the medium. The medium was also placed on top of the surrounding gel to prevent dehydration.

To study the effects of TGF- $\beta$ 1 on the MMP-8 mRNA expression, odontoblasts and pulp tissues were cultured for two days with or without human recombinant TGF- $\beta$ 1. The medium was replaced and collected daily. After the culturing procedure the cells were collected and the total RNA was isolated as described below.

#### **4.2.1.2 Pulp fibroblast (PF) cultures (I)**

The pulp samples for the human pulp fibroblast (PF) isolation were collected from the teeth that were removed as part of the normal treatment of patients. After dissecting the crown with pliers (for odontoblast culture), the pulp was gently removed with forceps and the tissue was cut into pieces and placed into cell culture clusters containing Dulbecco's modified Eagle's medium (DMEM) supplemented with foetal bovine serum (FBS) added with an antimicrobial component. The explants were then incubated at 37°C, collecting and replacing the medium twice a week. The cells were examined daily, and when the fibroblast outgrowth was observed the pulp tissue pieces were removed. After reaching the confluence, the fibroblast cell line was established by subsequent trypsinization and culturing through several passages. The cells were always allowed to reach the confluence before being subcultured. To analyse the MMP-8 mRNA production, the PF cells in passage two (n=2) were washed with PBS and the total RNA was isolated as described later.

#### **4.2.2 Plasma cells (IV)**

Human myeloma cell line RPMI 8226 (ATCC Number: CCL-155; Rockville, MD, USA) was cultured in RPMI 1640 medium (Gibco, Basel, Switzerland), supplemented with newborn calf serum, lactate glutamate and penicillin-streptomycin. Every third day, the cells were washed in phosphate-buffered saline (PBS) and the medium was renewed. After one week the cultured cells were separated to receptacles,  $9 \times 10^{10}$  cells in each, and cultured in serum-free culture medium for 24 hours. Differently combined cytokines, IL-6, heparin, TNF- $\alpha$ , and PMA, were added to the receptacles and after 24 hours the culture medium was centrifuged to separate the cells from the medium. About 10 000 cells were counted for the Western blot analysis described later.

### **4.3 Sample collection from root canals (II)**

The RTC was done under sterile conditions using rubber dam isolation. Primary access was done with low speed dental burs. The instrumentation of the root canal was started with 20 or 25 files and radiograph was taken to measure the working length. A sterile paper point was inserted into the canal for 2 minutes to absorb exudates from the canal. The root canals were widened to the desired width (minimum 40) with rinsing in between files. For the final rinsing with EDTA and NaOCl, the canal was dried before inserting Ca(OH)<sub>2</sub> paste for two weeks. After two weeks the access was re-opened and the canal was gently instrumented and rinsed with sterile saline solution before drying. A sterile paper point was again inserted into the canal for 2 minutes for periapical exudate collection. After two weeks, the same procedure was repeated and afterwards the root canal was filled with gutta-percha points and a sealer. After sample collections, the exudate from the absorbent points was diluted into a buffer and stored at -70 °C for further handling.

## 4.4 PCR analysis

### 4.4.1 RNA isolation (I and IV)

The total RNA was isolated from odontoblasts (native and cultured), pulp tissue cultures and pulp fibroblasts cultures, as well as from cultured RPMI 8226 myeloma cells using the Trizol® (Gibco BRL, Roskilde, Denmark) reagent isolation method. The RNA yield was measured by absorbance of 260 nm, and the samples were stored at -70°C until needed. RNA isolated from bone marrow cells (Hanemaaijer *et al* 1997) served as positive controls.

### 4.4.2 RT-PCR (I, III and IV)

For cDNA synthesis, a 20 µl reverse transcription reaction was carried out on 2 µg (plasma cells) and 1.7-11 µg (odontoblast and pulp cells) of the total RNA and random hexamer primers with Superscript™ II RNaseH-Reverse Transcriptase (Gibco BRL, Roskilde, Denmark) according to the product protocol. Specific primers for MMP-8 (not recognizing MMP-1 or other MMPs) were those designed as described by Hasty *et al* (1987). MMP-8 sense primer 5'-AAGGCAACCAATACTGGG, and MMP-8 antisense primer 5'-ATTTTCACGGAGGACAGG, with the expected product size of 522 base pair (bp), and MMP-8 nested sense primer was 5'-AGCAGCGTCCAAGCAATTG-3' and MMP-8 nested antisense primer 5'-AATGCATGCTGAACTTCCCTTC-3', with the expected product size of 352 bp. Specific primers for MMP-13 were designed based on the published DNA sequence (Freije *et al* 1994), MMP-13 sense primer 5'-AGATAAGTGCAGCTGTTCAC and MMP-13 antisense primer 5'-TCATTGACAGACCATGTGTC, with the expected product size of 572 bp. MMP-13 nested sense primer was 5'-AGCATCTGGAGTAACCGT-3' and MMP-13 nested antisense primer 5'-TCAATGTGGTTCCAGCCA-3', with the expected product size of 238 bp. 18S ribosomal RNA was used as a control for the RNA integrity using primers designed based on the published sequence (McCallum *et al* 1985).

PCR amplification reactions were performed with primers and Dynazyme™ DNA polymerase (Finnzymes Oy, Espoo, Finland) according to the product protocol and the linear area of the PCR reaction for each reaction was defined. The original amplification was performed as described by Hanemaaijer *et al* (1997). MMP-8 PCR amplification was done at 30-55 cycles and the nested MMP-8 PCR amplification was performed using 14-18 cycles, and MMP-13 PCR had 35 or 45 cycles and the nested 21-24 cycles. 18S PCR was done using 13 or 14 cycles. After finding the linear portion of each set of primers for the quantitation of the products, they were quantitated with ScionImage program. Values for MMP-8 and -13 cytokine inductions were calculated from the scanned densitometric values and related to the corresponding 18S values.

## 4.5 Southern blotting (I)

PCR products were fractionated on 1.5 % agarose gels, transferred to a nylon filter (Amersham, Buckinghamshire, UK) and hybridized as described elsewhere (Ausubel *et al* 1988). The specific cDNA probe for MMP-8 was prepared. The Southern filter was hybridized to a labelled MMP-8 cDNA probe in ExpressHyb hybridization buffer (Clontech, Palo Alto, CA, USA) for 1 hr at 60°C. The filters were washed in saline-sodium citrate (SSC)/ sodium dodecyl sulphate (SDS) at room temperature and exposed to x-ray film (Kodax X-OMAT).

## 4.6 Western immunoblotting and MMP-8 immunofluorometric assay (IFMA)

### 4.6.1 Western immunoblot analysis (I, II, and IV)

The molecular forms of MMP-8 and -13 were analysed by the Western blotting method utilizing the specific MMP-8 antibody (Hanemaaijer *et al* 1997) and specific polyclonal MMP-13 antibody (Freije *et al* 1994). The dissolved plasma cells, supernatant from the plasma cell culture, pure RPMI L-glutamine media and the root canal exudate samples were parallel treated with Laemmli's buffer without reducing reagents. To investigate the secretion of MMP-8 into the odontoblast and pulp cell culture medium and the effect of TGF- $\beta$ 1 on the amount of secreted protein, a conditioned serum-free OPTI-MEM medium, with and without TGF- $\beta$ , was used for the Western blot analysis. To investigate the secretion of MMP-8 into the odontoblast culture medium and the effect of TGF- $\beta$ 1 on the amount of secreted protein, a conditioned serum-free OPTI-MEM medium, with and without TGF- $\beta$ , was used for the Western blot analysis.

The samples were run on polyacrylamide gels by electrophoresis and electrotransferred onto a nitrocellulose membrane (Schleicher & Schuell, Dassel, Germany and Bio-Rad Laboratories, Richmond, CA, USA) (Hanemaaijer *et al* 1997). After blocking the non-specific binding sites with gelatin or non-fat dry milk (odontoblast and pulp cell samples), the membrane first reacted with the primary antibody and then with the alkaline phosphatase-conjugated secondary antibody (IV) or peroxidase-conjugated swine anti-rabbit immunoglobulins (I, II). The immunoreactive proteins were visualized by Nitro Blue Tetrazolium and 5-bromo-4-chloro-3-indolyl-phosphate or with diaminobenzidine tetrahydrochloride (DAB) and quantitated by the Imaging Densitometer (Prikk *et al* 2002).

### 4.6.2 MMP-8 immunofluorometric assay (IFMA) (I, II)

The concentration of the monoclonal MMP-8 secreted into the odontoblast and pulp tissue culture media, as well as the root canal exudate, was determined by a time-resolved immunofluorescence assay as described previously (Hanemaaijer *et al* 1997, Sorsa *et al* 1999). Conditioned culture medium samples, both with and without TGF- $\beta$ 1, were collected from the odontoblast organ and pulp tissue cultures. The monoclonal MMP-8 specific 8708 and 8706 antibodies were used as a catching antibody and the tracer antibody, the tracer antibody being labeled using europium chelate. Samples were diluted and incubated in assay buffer followed by incubation with the tracer antibody. An enhancement solution was added, and fluorescence was measured using a 1234 Delfia Research Fluorometer (Wallac, Turku, Finland). The monoclonal MMP-8 antibody specificity corresponded to that of the polyclonal MMP-8 antibody (Hanemaaijer *et al* 1997).

## 4.7 Preparation of RNA probes (III, IV)

For the preparation of RNA probes, an 845 bp *PstI-EcoRI* fragment of clone L15 of the Ln-5  $\gamma$ 2 chain was subcloned into the pSP64 and pSP65 vectors in the sense and antisense orientations (Kallunki *et al* 1992). A 635 bp *Sca I-Sac I* fragment of human MMP-2 cDNA clone was subcloned into the M13 polylinker site of the pSP64 and pSP65 vectors (Huhtala *et al* 1990). A 734 bp *BamHI-HindIII* fragment of human MMP-13 cDNA (Freije *et al* 1994) was ligated into the pGEM-4Z vector, and a 95 bp *HindIII-BamHI* fragment of human MMP-8 cDNA (Hasty *et al* 1990) was ligated into the pGEM-3Z vector. The probes were tested by Northern hybridization for specificity and by sequencing. The vectors were linearized with a suitable restriction enzyme and a riboprobe transcription kit (Boehringer Mannheim, Germany) was used for transcription.

The transcripts were labelled with digoxigenin (DIG)-11-UTP for *in situ* hybridization, and a corresponding sense probe was used as a control for nonspecific hybridization.

#### **4.8 *In situ* hybridization (III and IV)**

For *in situ* hybridization, all the solutions were treated with 0.1% diethylpyrocarbonate (DEPC). Paraffin sections from different odontogenic jaw cysts were processed prior to prehybridization, and *in situ* hybridization with DIG-labelled RNA-probes was done as described by Mäkelä *et al* (1999). The prehybridization buffer was removed and hybridization buffer containing 800 ng/ml DIG-labelled antisense or sense probe was applied to each section and hybridized overnight at 57°C. The posthybridization washes were done under stringent conditions as described by Mäkelä *et al* (1999). After washing, the sections were blocked and incubated with 1:100 diluted alkaline phosphatase-conjugated anti-DIG Fab-fragments and stained with alkaline-phosphatase substrate Fast Red (Boehringer Mannheim, Germany) and counterstained with Mayer's haematoxylin (Merck KgaA, Darmstadt, Germany).

#### **4.9 Immunohistochemical staining and evaluation of the staining**

##### **4.9.1 Immunostaining (I, II, III and IV)**

Immunohistochemistry was performed with different antibodies (Table 4) using VECTASTAIN® Elite ABC Kit (Vector Laboratories, Burlingame, CA, USA) according to the protocol. The fresh teeth preparates were fixed in methanol and demineralized in EDTA. Before immunohistochemical staining, they were pre-treated with bovine testicular hyaluronidase (Sigma, St. Louis, MO, USA) and methanol. Formalin-fixed paraffin sections were deparaffinized, hydrated, pre-treated with pepsin and with H<sub>2</sub>O<sub>2</sub> in methanol. Thereafter, all the sections were incubated with normal goat / horse serum, secondly with primary antibody, and then with biotinylated anti-rabbit / anti-mouse immunoglobulin G and with avidin-biotin complex. The sections were stained with 3-amino-9-ethylcarbazole (AEC) with the DAB Kit (Vector Laboratories, Burlingame, CA, USA) and counterstained with the Mayer's hematoxylin.

##### **4.9.2 Evaluation of immunostaining (III)**

The staining positivity and intensity of different MMPs in the basement membrane zone in the different types of odontogenic cysts was analysed using a modification of the method described by Bachmeier *et al* (2000). Briefly, ten randomly selected areas of two different microscopic slides of each cyst type were inspected with a light microscope using 200 x magnification. The length of the basement membrane zone observed in each area was 0.65 mm. A two step score was used for the positivity of staining (0: no positive staining, 1: positive staining). When staining was observed, the intensity was graded using a three-step scale (1: faint, 2: moderate, 3: strong positive staining). The results of the 20 independently inspected areas were summarized.

**Table 4. Antibodies used in immunohistochemistry**

Poly: polyclonal, Mono: monoclonal

<b>Antibody</b> (Ref. of source)	dilution	fixation of target tissue	pre-treatment	publications
<b>MMP-8</b> (Poly) (Hanemaaijer <i>et al</i> 1997)	1:350	96% cold methanol	testicular hyaluronidase	I
<b>MMP-8</b> (Poly) (Hanemaaijer <i>et al</i> 1997)	1:500- 1:800	10% formalin	pepsin	II, III, IV
<b>MMP-13</b> (Poly) (Golub <i>et al</i> 1997)	1:1000- 1:1300	10% formalin	pepsin	III, IV
<b>MMP-2</b> (Poly) (Westerlund <i>et al</i> 1996)	1:1000	10% formalin	pepsin	III
<b>Laminin-5</b> (Poly) (Salo <i>et al</i> 1999)	1:400	10% formalin	pepsin	III
<b>CD68</b> (Mono) (NeoMarkers, Fremont, Ca, USA)	1:60	10% formalin	pepsin	II
<b>NCL-PC</b> (Mono) (Novocastra, Newcastle-upon-Tyne, UK)	1:300	10% formalin	pepsin	IV

#### 4.10 Statistical analysis (II, III and IV)

To analyse the MMP-8 difference in the root canal exudate during root canal treatment visits the Kruskal-Wallis 1-way ANOVA and Mann-Whitney U-test were used (II). The non-parametric tests were used because of the absence of the normal distribution within each sample site group. The student's t-test was used when comparing the latent and active MMP-8 levels in the root canal exudate (II). To examine statistically the differences of the MMPs in the BM area between different odontogenic cysts, the Fisher's nonparametric exact test was used (III). The MMPs in plasma cells in different bone destructive lesions were analysed using the Chi-square test. A p-value less than 0.05 was considered significant (IV).

## 5. Results

### 5.1 Pulpal and periapical tissue

#### 5.1.1 MMP-8 in odontoblasts and pulp tissue

##### 5.1.1.1 Healthy pulp tissue (I)

###### Expression of MMP-8 mRNA

In healthy pulps from extracted third molars, the native and cultured odontoblasts and pulp tissue, as well as the cultured pulp fibroblasts, expressed MMP-8 mRNA by RT-PCR. The transcripts were identical to those from the positive control (bone marrow cells). The specificity of the PCR amplification was confirmed by a Southern blot analysis using a specific MMP-8 cDNA probe. TGF- $\beta$ 1 added to the cell culture down-regulated 10% and 25% the MMP-8 mRNA production in odontoblast and pulp tissue cultures.

###### Expression of MMP-8 protein

A Western blot analysis with MMP-8 antibody detected a 65 kDa immunoreactive band in all the native odontoblast, pulp and pulpal fluid samples from sound teeth. A fainter 50 kDa band was also detected in all the pulp and pulpal fluid samples, as well as from the conditioned odontoblast culture medium. A high molecular weight band (>100-112 kDa) of MMP-8 was detected in all the native samples. No characteristic PMN MMP-8 (75-80 kDa) isoform was observed. TGF- $\beta$ 1 had no observable effect on the MMP-8 level in the samples studied by the Western blot analysis. However, in the PCR analysis of secreted MMP-8 from the culture medium of odontoblasts and pulp tissue revealed a detectable down-regulation in the MMP-8 levels when TGF- $\beta$ 1 was added. The medium was collected after 24 and 48 hours of culturing. The MMP-8 levels in the odontoblast and pulp tissue medium were lower in both (24 and 48 h) samples cultured with TGF- $\beta$ 1.

Immunohistochemical staining with the same MMP-8 specific antibody revealed MMP-8 positivity in the odontoblast cell layer, localised to the odontoblast body. MMP-8 positivity was also detected in some, but not all, endothelial cells lining the pulp vessels.

##### 5.1.1.2 Pulp with inflammation (II)

###### Expression of MMP-8 protein

The Western blot analysis of the pulpitis tissue revealed intensely stained bands of 55-45 kDa, 75-80 kDa and 100-112 kDa. The 75-80 kDa band most likely represents the MMP-8 isoform from the PMNs. By immunohistochemistry, in addition to PMN cells, MMP-8 immunoreactivity was detected in the macrophage-like cells, plasma cells and some endothelial cells. The immunohistochemical analysis revealed that MMP-8 immunoreactivity accumulated around the pulp abscess.

#### 5.1.2 MMP-8 in the root canal exudate (II)

RTC clearly decreased the MMP-8 levels in the root canal exudate. However, in order to successfully minimize the MMP-8 concentration in the root canal exudate, the local calcium hydroxide paste medication was required for four weeks. After careful mechanical and chemical root canal preparation with local adjunctive medication for a fortnight, some MMP-8 could still be detected in some cases.

There was a statistically significant difference in the MMP-8 levels between the first and last root canal therapy visits (Kruskall-Wallis  $p=0.02$ ; Mann-Whitney U-test  $p=0.0107$ ).

The high (65-75 kDa) and low (45-55 kDa) molecular size MMP-8 isoforms detected in the root canal exudates were in both latent and active forms. If there was MMP-8 detectable in the root canal exudate during the second visit, the relative amount of the active form was elevated, but not significantly. The only case in which the MMP-8 level in the root canal exudate did not decrease during the root canal treatment, was later diagnosed to have a vertical fracture and the tooth needed to be extracted.

### 5.1.3 MMPs in apical periodontitis (II)

In CAP, MMP-8 was immunohistochemically detected mostly in the PMNs. In addition to the PMNs, MMP-8 protein was present in the subpopulation of macrophages and plasma cells. The histiocytic nature of the macrophages was confirmed by staining with the CD68 macrophage cell marker. NCL-PC positive plasma cells expressed MMP-8 in 2 out of 10 cases. In addition to the plasma cells MMP-13 protein expression was present in macrophages. Half of the samples studied expressed MMP-13 protein in the plasma cells and the MMP-13 mRNA expression was evidenced by *in situ* hybridization.

## 5.2 Odontogenic cysts

### 5.2.1 Laminin-5 (III)

The  $\gamma 2$  chain of Ln-5 was detectable by immunohistochemistry in the BM zone of all the RC, FC and KC samples studied. In the KC samples, the  $\gamma 2$  chain stained the basement membrane zone as a continuous ribbon. In 30% of the cases, a few epithelial cells stained positively. In the FCs, the Ln-5  $\gamma 2$  chain staining showed local breaks in the basement membrane zone in 64% of the cases. In the epithelial cells,  $\gamma 2$  chain positivity was present in 81% of the cases. In the RCs, the BM zone staining with the Ln-5  $\gamma 2$  chain antibody showed local breaks in 18% of the cases and the epithelial cells showed  $\gamma 2$  chain positivity in 91 % of the cases. Expression of Ln-5  $\gamma 2$  chain mRNA was observed in all cyst types in basal epithelial cells.

### 5.2.2 Expression of MMP-2 (III)

MMP-2 immunoreactivity was detected in the cyst capsule fibroblasts of all the cyst types studied (RC, FC and KC), and mRNA was also detected in some fibroblast-like cells of all the cysts. Only the KCs showed MMP-2 immunoreactivity in all the samples studied. MMP-2 protein expression was detected in the epithelium in all the cyst types studied, but clear expression of MMP-2 in basal cells and the BM zone was only in the detached epithelium of the KCs. There was a statistical difference in the location of the MMP-2 expression in the BM area between the KC and RC ( $p=0.023$ ). The difference was clear but not statistically significant between the KC and FC ( $p=0.0698$ ). The quantity and intensity of the MMP-2 staining in the BM area was clearly higher in the KCs than the other cyst types studied.

### 5.2.3 Expression of MMP-8 (III, IV)

MMP-8 immunoreactivity was detected in all the cyst types studied, mainly in the connective tissue cyst capsule. PMNs, plasma cells and FC foam cells (phagocytic macrophages) expressed MMP-8. In the epithelium, MMP-8 protein was observed in the FC goblet cells. Plasma cells in the FCs (6/10) stained more often positively with MMP-8 antibody than those in the RCs (2/10)

and KCs (1/7). MMP-8 mRNA was detectable in plasma cells and foam cells, as well as in epithelial goblet cells and some epithelial cells of the FCs. In the FCs both protein and mRNA of MMP-8 could be observed in the same plasma cell accumulation. Interestingly, MMP-8 expression appears to be seen in the FCs more often than in the other (RC and KC) cyst types.

#### **5.2.4 Expression of MMP-9 (unpublished results)**

MMP-9 was expressed by PMNs in cyst capsules and infiltrating in the epithelium, and cyst capsule plasma cells in KCs and RCs. MMP-9 mRNA was detected in osteoclasts in the bony front of cyst capsule. MMP-9 expression was not detected in the jaw cyst lining epithelial cells.

#### **5.2.4 Expression of MMP-13 (III, IV)**

MMP-13 protein was observed in all the KCs. MMP-13 positivity could be observed in the plasma cells of the KC cyst capsule close to the lining epithelium and in the epithelial cells, as well as in small satellite cyst epithelial cells in the cyst capsule. In 55% of the KCs, MMP-13 expression was detectable in the BM zone. In the RCs, the number of positive cases was about half that observed in the KCs. MMP-13 mRNA was present in the plasma cells and epithelial cells of the KCs and in some cyst capsule fibroblasts as well. Statistical analysis showed a significant elevation in MMP-13 expression in KC plasma cells compared to the RCs and FCs. When comparing the epithelial expression, a significant difference was detected between the KCs and FCs ( $p=0.0294$ ), but not between the KCs and RCs ( $p=0.6372$ ). The quantity and intensity of MMP-13 immunostaining was clearly higher in the KCs than in the FCs and RCs.

### **5.3 Multiple myeloma and plasmacytoma**

#### **5.3.1 Plasmacytoma tissue samples (IV)**

##### **5.3.1.1 MMP-8**

In the PLC tissue samples, MMP-8 expression was only slightly observable by immunohistochemistry, but *in situ* hybridization was negative.

##### **5.3.1.2 MMP-13**

Clear MMP-13 immunoreactivity was detected in 80% of the PLCs (no expression was detected in one tonsil, as well as the bone marrow and tongue PLC samples). Statistical analysis revealed significantly enhanced MMP-13 expression in the PLC samples in comparison to the RC and FC samples. No significant difference was detected when compared with the KCs. Of the three samples studied by *in situ* hybridization, MMP-13 mRNA expression was revealed in malignant PLC plasma cells in bone marrow and the upper jaw mucous membrane, but not in the vertebral lesions.

#### **5.3.2 Multiple myeloma cell cultures (IV)**

We studied the MMP production *in vitro* in the human myeloma cell line RPMI 8226. The cells were treated with PMA, cytokines (IL-6 and TNF- $\alpha$ ) or heparin, alone or in different combinations. The results were analysed by RT-PCR and Western blotting.

### **5.3.2.1 MMP-8 expression**

MMP-8 mRNA and protein was observed in cultured RPMI plasma cells. By Western blotting clear immunoreactive bands were detected in the cell lysates, but not in the culture media. MMP-8 immunoreactivity was clearly enhanced by IL-6 alone and combined with TNF- $\alpha$ . A combination of heparin with cytokines and PMA further induced MMP-8 immunoreactivity. MMP-8 mRNA expression was also increased by PMA, TNF- $\alpha$  and IL-6 in cultured RPMI 8226 cells. In 24 hours the MMP-8 mRNA was upregulated by 9.1 (PMA), 4.7 (TNF- $\alpha$ ) and 7.2-fold (IL-6). The MMP-8 induction was more clearly presented in the RT-PCR than in the Western blot, probably due to a delay in protein expression.

### **5.3.2.2 MMP-13 expression**

The RT-PCR and Western blot showed MMP-13 expression in the RPMI 8226 malignant plasma cell line. Detected by the RT-PCR PMA, TNF- $\alpha$  and IL-6 upregulated the MMP-13 mRNA expression by 6.1-, 8.7- and 6.8-fold, and the induction was enhanced when the cytokines were combined with heparin. MMP-13 protein was detected in the plasma cell lysates but not in the culture media. IL-6 alone and combined with TNF- $\alpha$  increased the MMP-13 immunoreactivity. Heparin combined with cytokines and PMA also increased the MMP-13 expression slightly. The RT-PCR presented increased MMP-13 expression more clearly than the Western blot.

## 6. Discussion

### 6.1 The role of MMPs in pulpal and periapical tissue and root canal exudate

#### 6.1.1 MMPs in pulp tissue (I, II)

Pulpal cells can express various MMPs, including MMP-1, MT1-MMP, MMP-20 (Llano *et al* 1997, Lin *et al* 2001, Palosaari *et al* 2002), and MMP-2 (Tjäderhane *et al* 1998, Chang *et al* 2001) *in vitro*, and MMP-20 *in vivo* (Sulkala *et al* 2002). Bacteria and their virulence factors (toxins) upregulate MMP-2 expression and secretion by pulp cells (Chang *et al* 2002). Most of the studies done have utilized pulp tissue cells and fibroblasts, but odontoblasts have lacked a good *in vitro* study model. The new odontoblast culturing method described by Tjäderhane *et al* (1998) has provided a new way to reveal molecular events and processes associated with the healthy and diseased pulp and its cellular components. As recently shown, odontoblasts can express different MMPs: MMP-2, -9, -20 and MT1-MMP (Llano *et al* 1997, Tjäderhane *et al* 1998, 2001, Palosaari *et al* 2002), and, according to the present results, MMP-8 as well (I). TGF- $\beta$  can upregulate MMP-9 expression, and down-regulate MMP-2 synthesis (Tjäderhane *et al* 1998), but has no effect on collagen synthesis in odontoblasts (Palosaari *et al* 2001). The present study further revealed that TGF- $\beta$  has a reducing effect on MMP-8 synthesis in mature odontoblasts (I). TGF- $\beta$  is a multifunctional growth factor found in dentin, and it is thought to regulate tissue repair in the tooth (Lesot *et al* 1994). The downregulation of MMP-8 may be a factor leading to a reparative dentin formation because it is regarded as essential for modulating tissues during normal dentin formation. It is evident that MMPs expressed by odontoblasts may have a role in dentin and reparative dentin formation and the growth factors can act as MMP regulators, as well as regulate collagen synthesis.

A strong expression of MMP-8 in the inflammatory cells of pulpitis tissue was seen. Studies have shown that bacteria and their products upregulate MMP-1 and MMP-2 in pulp cells, but have no effect on MMP-9 (Nakata *et al* 2000, Chang *et al* 2002). The levels of MMP-1, -2, and -3, expressed mainly by monocyte/macrophages and fibroblasts, are significantly higher in acute pulpitis tissue than in healthy pulp tissue (Shin *et al* 2002). Bacterial products irritate PMNs to release MMP-8 (Ding *et al* 1996, 1997), and proinflammatory cytokines upregulate MMP-1 and MMP-2 in the pulpal tissue (Tamura *et al* 1996, O'Boskey *et al* 1998, Chang *et al* 2001). The bacteria and their products may act in pulpal inflammation by upregulating cytokine production and via the cytokine pathway increase MMP expression and directly irritate cells to produce MMPs. The MMP-8 in pulpal inflammatory lesions was mainly of PMN origin. PMNs are cells forming pulp abscesses and, thus, activated MMP-8 may well participate in the tissue destruction of pulp necrosis and abscesses. PMNs are migrating and recruiting cells able to penetrate dentinal tubules (Bergenholtz 2000), and they may well need MMP-8 for this. Western blot bands 55-45 and 100-112 kDa probably represent the MMP-8 isoform originating from the non-PMN lineage cells (Hanemaaijer *et al* 1997). MMP-8 species higher than 90 kDa possibly represented high molecular size MMP-8 complexes formed after binding to inhibitors (TIMPs,  $\alpha$ 2M) and/or dimerization (Prikk *et al* 2001, 2002).

#### 6.1.2 MMPs in periapical tissue and root canal exudate (II, IV)

Untreated tooth necrosis usually leads to CAP, a destructive inflammatory condition around the tooth apex. It is a complicated process including bacteria and their products, immunoglobulins, proinflammatory cytokines and other inflammatory mediators affecting each other in a complex

manner. PMNs, being the first cellular barrier to bacterial invasion, may, in addition to digesting bacteria, destroy surrounding tissue compartments by secreting MMPs, especially MMP-8. PMN cells, induced by bacterial products or toxins, can release proinflammatory cytokines (Barkhordar *et al* 1992) which autocrinically stimulate PMNs to release MMP. Plasma cells, which enter the inflammatory tissue after the PMNs, secrete immunoglobulins and also express MMP-8 and MMP-13 (IV). Macrophages are the major inflammatory cells in CAP. They take part to PMN and lymphocyte activation and are considered to be the major source of IL-1 $\alpha$ , IL-1 $\beta$  and TNF- $\alpha$ . MMP-1, -2 and -3 immunoreactivity has been detected in the inflammatory cells (plasma cells, lymphocytes and macrophages) of periapical lesions (Shin *et al* 2002). Monocytes/macrophages express MMP-8 and MMP-13 (Prikk *et al* 2001, Kiili *et al* 2002), and these MMPs may work not only extracellularly taking part in tissue destruction, but also intracellularly in the phagocytic process. The osteoclasts are responsible for gnawing the bone at the periphery of CAP (Bohne 1990, Anan *et al* 1991). This "bony digestion" can well be, at least partially, due to MMPs, especially by MMP-9 secreted by osteoclasts (Reponen *et al* 1994, Wucherphennig *et al* 1994). Being able to activate proMMP-9, MMP-13 (Knäuper *et al* 1997) has the potential to act as a proMMP-9 activator in CAP. The MMPs secreted by cells other than osteoclasts in CAP may, thus, be responsible for the degradation of the ECM particles and the waste products appearing after osteoclast bone dissolution during CAP formation.

The inflammatory process and tissue destruction in CAP, at least in part, resembles the same phenomenon in periodontitis provoked by putative periodontopathogenic bacteria (Ding *et al* 1996, 1997). The oral bacteria trigger MMP release and activation by the PMN cells (Ding *et al* 1997) and in periodontitis the MMPs, and especially their activation, have a pivotal role in periodontal tissue destruction and are considered to be a key biochemical marker of active periodontal disease (Sorsa *et al* 1994, 1995, 1999, Ingman *et al* 1996, Tervahartiala *et al* 2000, Kiili *et al* 2002, Mäntylä *et al* 2000, 2003). It is likely that in addition to other bone destructive mechanisms present (Fig. 2), the MMPs exert a destructive role in CAP as well (II, IV).

The main focus of RCT in CAP is to eliminate the bacteria, their virulence factors and toxins and associated inflammatory reaction in the apical area. As a result, bacteria and their products no longer continue the inflammatory process and the level of inflammatory cells diminishes. RCT, by eventually reducing the infective bacteria and the apical inflammatory reaction, diminishes the active and latent forms of MMP-8 in the root canal exudates and, thus, the MMP-8 dependent inflammatory tissue destruction in apical area is also decreased (II). Finding of MMP-8 in the root canal exudate even after the root canal was cleaned by chemical and mechanical means shows that the MMP-8 must be of periapical origin and that the inflammatory process in the apical area is diminishing slowly but clearly during three weeks (II). Detection of decreased MMP-8 levels during RCT may lead to adjunctive chair-side or point-of-care diagnostic tools similar to the one developed for periodontitis GCF and peri-implant sulcular fluid (PISF) (Sorsa *et al* 1999, Kivelä-Rajamäki *et al* 2003, Mäntylä *et al* 2003) to evaluate the periapical inflammation process during RCT (II). In this regard, chemical compounds, such as chlorhexidine, often used as adjunctive medication in the periapical, as well as in periodontal, treatment in addition to its antimicrobial properties, exert properties directly *in vitro* and *in vivo* to inhibit the MMPs and their oxidative activation including MMP-8 (Sorsa *et al* 1990, Gendron *et al* 1999, Azmak *et al* 2002, Mäntylä *et al* 2003).

## 6.2 MMPs and Ln-5 in odontogenic cysts (III, IV)

KC is the most aggressive bone destructive odontogenic jaw cyst with a strong tendency to recur. This is considered to be mainly due to the epithelial detachment. KC epithelium also proliferates rapidly compared to other odontogenic cysts. Many MMPs have been detected in odontogenic jaw cyst tissue extracts and cultured cyst cells, but so far only MMP-1 has been located on the

cellular level to the cyst epithelium (Lin *et al* 1997). In addition, KC epithelial cells in culture have been shown to secrete proMMP-9 and proMMP-3 (Kubota *et al* 2000). Certain MMPs, such as MT1-MMP, MMP-2 and MMP-13 are able to process the Ln-5  $\gamma$ 2 chain (Giannelli *et al* 1997, 1999, Koshikawa *et al* 2000, Pirilä *et al* 2001b, 2003). Epithelial cell migration and detachment from the BM zone is regulated partially through Ln-5 processing (Giannelli *et al* 1997, 1999, Koshikawa *et al* 2000, Gilles *et al* 2001). Pirilä *et al* (2003) have recently shown that MMP-3, -8, -12, -14 and -20 can process Ln-5. However, only the processing of the  $\gamma$ 2 chain by MT1-MMP, MMP-2 and MMP-13, but not MMP-8, induces epithelial cell migration (Giannelli *et al* 1997, 1999, Pirilä *et al* 2003). In KCs, the  $\gamma$ 2 chain of Ln-5 was co-located with MMP-2 and -13 in the BM zone (III). In other cysts (RC, FC) the MMPs studied did not localize to the BM zone (III). These co-localization results in KCs indicate that particularly MMP-2 and -13 and Ln-5 may be involved in the specific molecular processes in the KC epithelium. By splitting the Ln-5  $\gamma$ 2 chain, they may evoke epithelial proliferation and migration in KCs. MMP-2 and MMP-13 can also cleave collagen IV, the Ln-5 binding site in BM, and MMP-2 also cleaves the anchoring filament type VII collagen (Rousselle *et al* 1997). MMP-2 expression is particularly strong in the BM of KCs when epithelial detachment occurs. This suggests that MMP-2 has a role in the loosening of the KC epithelium caused by Ln-5 degradation and maybe collagen VII breakdown. MMP-13, together and activated by MMP-2, could contribute to the epithelial migration and growth induced by Ln-5 and collagen IV cleavage.

The localization of MMP-8 in the FC cyst epithelium, but not in the BM zone, fits the less aggressive clinical outcome of FCs. The presence of MMP-8 in secreting cells (goblet cells) suggests that goblet cell-derived MMP-8 contributes to the dissolution of the cyst lumen material and eventually affects the osmotic pressure. MMP-9 expression was not detected in epithelial cells either by immunohistochemistry or *in situ* hybridization, although the epithelial cells of KCs produce pro-MMP-9 in cell culture (Kubota *et al* 2000). Instead, MMP-9 was detected in plasma cells and PMNs invading in the cyst epithelium probably targeting the cyst lumen. MMP-8 positive PMNs were also detected between the epithelial cells in odontogenic cysts.

Earlier studies have shown MMP-1, MMP-2, MMP-8 and MMP-9 in jaw cyst fluids and tissue extracts (Teronen *et al* 1995a, b, Kubota *et al* 2000), and MMP-2 together with MT1-MMP has been found in cultured KC fibroblasts (Kubota *et al* 2002). MMP-1 is also detected in fibroblasts, endothelial cells and osteoblasts in RCs (Lin *et al* 1997). In addition to the cyst epithelium, the investigation revealed the presence of MMP-2, -8 and -13 in cyst capsule cells, mainly fibroblasts, and in inflammatory cells, PMNs and plasma cells.

The expression of different bone resorption stimulative cytokines (IL-1 $\beta$ , TNF- $\alpha$ ) and prostaglandins is also found in odontogenic cysts (Meghji *et al* 1996, Li *et al* 1997). Thus they may well act as MMP up-regulators during the growth and expansion of cysts. For example, IL-1 adds, collagen I induced, MT1-MMP production and proMMP-2 activation in KC fibroblasts (Kubota *et al* 2002). Osteoclasts are the front line cells in bone resorptive areas (Formigli *et al* 1995), and MMP-9 mRNA was present in osteoclasts in the bony front of the cyst capsule. MMP-2 mRNA was mainly detected in the fibroblast-like cells (III). Thus, MMP-2 could mainly be taking part in ECM modulation within the cyst capsule, while MMP-9 might be involved in the osteoclastic bone dissolution. MMP-8 and MMP-9 protein was present in PMNs in the cyst capsule in all cyst types studied. MMP-8 and MMP-9 containing PMNs are able to invade the whole cyst capsule and epithelium possibly enhancing the levels of these MMPs in the cyst lumen fluid, where they have also been previously detected (Teronen *et al* 1995a, b, Kubota *et al* 2000). Plasma cells were able to express MMP-8, -9 and -13, although MMP-13 was mainly found in the KC plasma cells. MMP-13 is closely connected to tumours and malignancy (Kähäri and Saarialho-Kere 1999) and KCs are partly regarded as benign neoplasm (Shear 2002a). Thus, it is tempting to speculate that catalytically competent and efficient MMP-13 strengthens the suggested neoplastic nature of KCs (Shear 2002b, c). In fact, MMP-13 might, at least partially,

explain the special growth pattern of KCs both by efficiently degrading the epithelium and the BM, as well as dissolving the connective tissue underneath.

### 6.3 MMPs in multiple myeloma (IV)

MM and PLC are bone destructive lesions where the bone tissue is replaced by malignant monoclonal plasma cells (Neville *et al* 2002). The expression of both MMP-13 mRNA and protein in the malignant plasma cells of plasmacytoma specimens was evident (IV), and MMP-13 is expressed in other malignancies as well (Airola *et al* 1997). Thus MMP-13 might participate in the destruction of normal tissue in order to allow the growth of malignant cells (Thomas *et al* 2000). The growth of MM is affected by various cytokines, of which IL-6 is considered to be the most important (Sati *et al* 1998, Lauta 2001). Plasma cells in chronic inflammatory diseases can produce other cytokines, such as TNF- $\alpha$  (DiGirolamo *et al* 1997). MM cells express gelatinases, of which MMP-2 is further connected to the increased angiogenic and invasive potential of bone marrow plasma cells (Vacca *et al* 1999) and MMP-7 being also expressed by MM cells is capable of activating latent MMP-2 (Barille *et al* 1999). The secretion of MMP-8 and MMP-13 by cultured RPMI 8226 myeloma cells was confirmed and the expression was enhanced by different cytokines including IL-6 and TNF- $\alpha$  (IV). In earlier studies, IL-6 has not been detected to affect MMP expression. The presence of MMP-13 protein and mRNA in plasmacytoma tissue specimens was shown by immunohistochemistry and *in situ* hybridization. The ability of MM cells to express different MMPs, especially the collagenolytic and serpinolytic MMP-8 and MMP-13, might be necessary for the invasive and tissue destructive potential of MM. Thus, MMP inhibitors including bisphosphonates alone or in combination with other MMP selective or broad-spectrum inhibitors or cancer drugs may, in future, be a new putative medication for this lethal disease (Derenne *et al* 1999, Koivunen *et al* 1999, Teronen *et al* 2000, Llawaneras *et al* 2001, Heikkilä *et al* 2002, 2003).

## 7. Conclusions

ECM and BM breakdown takes place in many normal and pathological conditions, such as inflammation and tumour growth. Collagenases (MMP-1, -8 and -13) and gelatinases (MMP-2 and -9) are MMPs capable of degrading almost all ECM and BM components. These enzymes are known to be effective in various inflammatory and other tissue destructive diseases.

The study shows the presence of MMP-8 in mature human odontoblasts and pulp tissue and TGF- $\beta_1$  reduced the MMP-8 mRNA expression in odontoblastic cell cultures. The MMP-8 detected by Western blot was the isoform of non-PMN lineage cells. The presence of MMP-8 in healthy odontoblasts and pulp tissue suggests that MMP-8, an efficient inducer of type I collagenolysis, may contribute to the modulation of dentin and secondary dentin formation.

In pulpitis, the MMP-8 was expressed in various inflammatory cells, such as PMNs, macrophages, plasma cells and in endothelial cells. In pulpitis, MMP-8 was considered to originate from both PMN and non-PMN lineage cells. The main MMP-8 positivity was accumulated around the pulp abscess suggesting that it also contributes to the abscess formation.

In root canal exudates, MMP-8 levels decreased during root canal treatment. Both active and latent MMP-8 were detected. Immunohistochemistry revealed MMP-8 in CAP tissue mostly in PMNs, but occasionally also in macrophages and plasma cells. MMP-13 was seen in some macrophages and plasma cells, a finding also evidenced by *in situ* hybridization. These results allow one to presume that collagenases are actively taking part in the tissue destruction and granulation tissue formation in CAP.

To be able to expand odontogenic cysts need to destroy the bone tissue ahead and their epithelium needs to proliferate. A KC is an odontogenic cyst with special characters due to its growth and epithelial proliferation manners. Ln-5 is a basement membrane protein being connected to both epithelial adhesion and migration. MMP-2, -8 -13 and MT1-MMP cleave Ln-5 though only MMP-2, -13 and MT1-MMP degrade the Ln-5  $\gamma_2$  chain into a form able to induce epithelial cell migration. Co-localization of Ln-5, MMP-2 and MMP-13 was present in the KC basement membrane zone but not in other odontogenic cysts studied. Based on this it is suggested that these MMPs, being able to degrade Ln-5, are partially responsible for the epithelial proliferation and detachment of the KC epithelium. MMP-8 was mainly detected in the goblet cells of FC epithelium. In cyst capsules, MMP-2 was detected in fibroblast-like cells, MMP-8 in PMNs, plasma cells and foam cells, mainly in FCs. MMP-9 was detected in osteoclasts in the bony front and MMP-13 was detected in some fibroblasts-like cells and plasma cells mainly in KCs. These findings suggest that both collagenases and gelatinases are active in the cyst enlargement and tissue rebuilding in cyst capsule formation. MMP-13 was found mainly in KCs, speaking for its neoplastic nature.

MM and PLC are tissue destructive monoclonal plasma cell malignancies. In order to expand, they need to destroy the normal tissue. MMP-8 and MMP-13 expression was detected in MM cell cultures and the expression of both was enhanced by cytokines and PMA. In PLC tissue, MMP-13 expression was detected by immunohistochemistry and *in situ* hybridization. There was a significant difference in the expression of MMP-13 between PLCs and benign cysts and apical periodontitis tissues. This confirms the notion of MMP-13 being present and operating especially in malignant lesions.

## ACKNOWLEDGEMENTS

Laboratory studies of this work were carried out at the Institute of Dentistry, University of Helsinki, Helsinki, Finland, Biomedicum Research Laboratory, Institute of Dentistry, University of Helsinki, Helsinki, Finland, and the Institute of Dentistry, University of Oulu, Oulu, Finland during 1997-2002. I wish to thank Professor Heikki Murtomaa, the former Dean of Helsinki University, and Professor Jukka H Meurman, the present Dean of Helsinki University, for placing the research facilities at my disposal. The periapical exudates collection took place at a private dental clinic: Ala-Malmin Hammaslääkärit, Helsinki, Finland, and I wish to thank Ari Kalliomäki, DDS, for giving me the opportunity to collect the samples at his Dental office.

I warmly thank my supervisors: Professor Tuula Salo, Professor Timo Sorsa, and associate Professor Olli Teronen who opened up the scientific world of matrix metalloproteinases for me, together with Professor Jarkko Hietanen who introduced me to the interesting field of oral pathology. It was a great pleasure to work with such innovative supervisors. I also owe my gratitude to my two “unofficial” supervisors and friends Professor Päivi Maisi (in memoriam) and Professor Leo Tjäderhane with whom I shared many creative discussions. The positive, encouraging attitude of all my wonderful supervisors was needed to push me through this thesis work. Thank YOU!!!

I wish to thank my reviewers Associate Professor Tuula Ingman and Professor Ylermi Soini for their constructive criticism and thorough reviewing of my thesis. I would also like to express my gratitude to Roderick Dixon for revising the language of this work and Helene Javen who checked the reference list.

My sincere thanks go to all my colleagues and co-workers in the Universities of Helsinki and Oulu. Special thanks goes to Emma Pirilä, MSc, and Taina Tervahartiala, DDS, PhD, who helped me so much in questions dealing with laboratory work. All the other colleagues, including Nina-Li Avellan, DDS, Pia Heikkilä, DDS, Anne Järvensivu, DDS, Marjo Kivelä-Rajamäki, DDS, Kaiu Prikk, MD, PhD, and Mathias Stenman, DDS, as well as other friends from the Universities of Helsinki and Oulu deserve my special thanks too. We have shared so many unforgettable moments together and working without you would have been so dull. You made the work joyable and full of laughter! Thanks!! ☺

I also express my gratitude to my other coauthors: Professor Markku Larmas, Hannele Luoto, MSc, Heidi Palosaari, DDS, PhD, Meeri Sutinen, MSc, and Anu Väänänen, MSc.

The laboratory staff, including “the boss” Kirsti Kari, MSc, Marjatta Kivekäs, Annikki Siren, and others, also deserve my gratitude. Their work made it possible for me to carry out the laboratory work needed for this thesis. I also thank my cousin Gina Braxenholm for her invaluable help with the statistics and I owe my warmest thanks to Assistant Professor Pirjo-Liisa Lukinmaa for her “mental tutoring”. I am also grateful to Marjo Kostia for her help in questions dealing with book-printing.

My warm thanks go to the staff at the private dental clinic, Ala-Malmin Hammaslääkärit, for being so patient with me while I was collecting the root canal samples and during all this time they have been so patient regarding my changing working hours.

All my friends and relatives get a big hug from me for being there for me when I needed people to talk to, especially Pirjo, Raija, Saira, the two Sirpas, Sussa, and “Pulmuset”. Thank You for putting up with me for all these years. Do not stop now! 😊

And last but not least, I wish to express my gratitude to the most important people in my life: Ari, Ville and Saara. I could not have done this without your love and support. I love You! 😊

This thesis study was supported by the Academy of Finland, the HUCH- and OUCH-EVO grants, the Wilhelm and Else Stockman Foundation and the Helsinki University Research Funds, and my personal grants from the Finnish Female Dentist Association and the Finnish Dental Society, which I gratefully acknowledge.

## References

- Aimes RT, Quijley JP.** Matrix metalloproteinase-2 is an interstitial collagenase. Inhibitor free enzyme catalyzes the cleavage of collagen fibrils and soluble native type I collagen generating the specific 3/4- and 1/4-length fragments. *J Biol Chem* **1995**; 270: 5872-5876.
- Airola K, Johansson N, Kariniemi AL, Kähäri VM, Saarialho-Kere UK.** Human collagenase-3 is expressed in malignant squamous epithelium of the skin. *J Invest Dermatol* **1997**; 109: 225-231.
- Ala-Aho R.** Human collagenase-3 (MMP-13) in tumor growth and invasion. Dissertation. Turku: University of Turku ; **2002**
- Amano S, Akutsu N, Matsunaga Y, Kadoya K, Nishiyama T, Champlaud M-F, Burgeson RE, Adachi E.** Importance of balance between extracellular matrix synthesis and degradation in basement membrane formation. *Exp Cell Res* **2001**; 271: 249-262.
- Andrew EM, Plater-Zyberk C, Brown CM, Williams DG, Maini RN.** The potential role of B-lymphocytes in the pathogenesis of rheumatoid arthritis. *Br J Rheumatol* **1991**; 30 (Supl 1): 47-52.
- Anan H, Akamine A, Hara Y, Maeda K, Hashiguchi I, Aono M.** A histochemical study of bone remodeling during experimental apical periodontitis in rats. *J Endod* **1991**; 17: 332-337.
- Angel P, Karin M.** The role of Jun, Fos and the AP-1 complex in cell-proliferation and transformation. *Biochim Biophys Acta* **1991**; 1072: 129-157.
- Apte SS, Mattei MG, Olsen BR.** Cloning of the cDNA encoding human tissue inhibitor of metalloproteinase-3 (TIMP-3) and mapping of the TIMP-3 gene to chromosome 22. *Genomics* **1994**; 19: 86-90.
- Artese L, Piattelli A, Quaranta M, Colasante A, Musani P.** Immunoreactivity for interleukin 1 $\beta$  and tumor necrosis factor- $\alpha$  and ultrastructural features of monocytes/macrophages in periapical granulomas. *J Endod* **1991**; 17: 483-487.
- Atkinson JJ, Senior RM.** Matrix metalloproteinase-9 in lung remodeling. *Am J Respir Cell Mol Biol* **2003**; 28: 12-24.
- Autio-Harmainen H, Hurskainen T, Niskasaari K, Höyhty M, Tryggvason K.** Simultaneous expression of 70 kilodalton type IV collagenase and type IV collagen  $\alpha$  1(IV) chain genes by cells early human placenta and gestational endometrium. *Lab Invest* **1992**; 67: 191-200.
- Azma N, Atilla G, Luoto H, Sorsa T.** The effect of subgingival controlled-release delivery of chlorhexidine chip on clinical parameters and matrix metalloproteinase-8 levels in gingival crevicular fluid. *J Periodontol* **2002**; 73: 608-615.
- Bachmeier BE, Nerlich AG, Boukamp P, Lichtinghagen R, Tschesche H, Fritz H, Fink E.** Human keratinocyte cell lines differ in the expression of the collagenolytic matrix metalloproteinases -1, -8, and -13 and of TIMP-1. *Biol Chem* **2000**; 381: 509-16.
- Bando Y, Henderson B, Meghji S, Poole S, Harris M.** Immunocytochemical localization of inflammatory cytokines and vascular adhesion receptors in radicular cysts. *J Oral Pathol Med* **1993**; 22: 221-227.
- Bannikov GA, Karelina TV, Collier IE, Marmer BL, Goldberg GL.** Substrate binding of gelatinase B induces its enzymatic activity in the presence of intact propeptide. *J Biol Chem* **2002**; 277: 16022-16027.
- Balbin M, Fueyo A, Knäuper V, Pendas AM, López JM, Jiménez MG, Murphy G, López-Otín C.** Collagenase 2 (MMP-8) expression in murine tissue-remodeling process. Analysis of its potential role in postpartum involution of the uterus. *J Biol Chem* **1998**; 273: 23959-23968.
- Barille S, Akhouni C, Collette M, Mellerin MP, Rapp MJ, Haraousseau JL, Bataille R, Amiot M.** Metalloproteinases in multiple myeloma: production of matrix metalloproteinase-9 (MMP-9), activation of proMMP-2, and induction of MMP-1 by myeloma cells. *Blood* **1997**; 90: 1649-1655.
- Barille S, Bataille R, Rapp M-J, Haraousseau J-L, Amiot M.** Production of metalloproteinase-7 (matrilysin) by human myeloma cells and its potential involvement in metalloproteinase-2 activation. *J Immunol* **1999**; 163: 5723-5728.
- Barkhordar RA.** Determining the presence and origin of collagenase in human periapical lesions. *J Endod* **1987**; 13: 228-232.
- Barkhordar RA, Hussain MZ, Hayashi C.** Detection of interleukin 1-beta in human periapical lesions. *Oral Surg Oral Med Oral Pathol* **1992**; 73: 334-336.
- Bergenholtz G.** Evidence for bacterial causation of adverse pulpal responses in resin-based dental restorations. *Crit Rev Oral Biol Med* **2000**; 11: 467-480.
- Bezerra MM, Brito GA, Ribeiro RA, Rocha FA.** Low-dose doxycycline prevents inflammatory bone resorption in rats. *Braz J Med Biol Res* **2002**; 35: 613-616.
- Birkedal-Hansen H, Moore WG, Bodden MK, Windsor LJ, Birkedal-Hansen B, DeCarlo A, Engler JA.** Matrix metalloproteinases: a review. *Crit Rev Oral Biol Med* **1993**; 4: 197-250.
- Bohne W.** Light and ultrastructural studies of human chronic periapical lesions. *J Oral Pathol Med* **1990**; 19: 215-220.
- Bredow DC von, Cress AE, Howard EW, Bowden GT, Nagle RB.** Activation of gelatinase-tissue-inhibitors-

- of-metalloproteinase complexes by matrilysin. *Biochem J* **1998**; 331: 965-972.
- Carter** A, Merchav S, Silvian-Draxler I, Tatarsky I. The role of interleukin-1 and tumour necrosis-alpha in human multiple myeloma. *Br J Haematol* **1990**; 74: 424-431.
- Chang** YC, Yang SF, Hsieh YS. Regulation of matrix metalloproteinase-2 production by cytokines and pharmacological agents in human pulp cell cultures. *J Endod* **2001**; 27: 679-682.
- Chang** YC, Lai CC, Yang SF, Chan Y, Hsieh YS. Stimulation of matrix metalloproteinases by black-pigmented *Bacteroides* in human pulp and periodontal ligament cell cultures. *J Endod* **2002**; 28: 90-93.
- Cootauco** CJ, Rauschenberger CR, Nauman RK. Immunocytochemical distribution of human PMN elastase and cathepsin-G in dental pulp. *J Dent Res* **1993**; 72: 1485-1490.
- Cowell** S, Knäuper V, Steward M, d'Ortho MP, Stanton H, Hembry R, López-Otín C, Reynolds JJ, Murphy G. Induction of matrix metalloproteinase activation cascades based on membrane-type 1 matrix metalloproteinase: associated activation of gelatinase A; gelatinase B and collagenase 3. *Biochem J* **1998**; 331: 453-458.
- Curran** S, **Murray** GI. Matrix metalloproteinases: molecular aspects of their roles in tumour invasion and metastasis. *Eur J Cancer* **2000**; 36: 1621-1630.
- Derenne** S, Amiot M, Barilee S, Collette M, Robillard N, Berthaud P, Harousseau JL, Bataille R. Zoledronate is a potent inhibitor of myeloma cell growth and secretion of IL-6 and MMP-1 by the tumoral environment. *J Bone Miner Res* **1999**; 14: 2048-2056.
- Deryugina** EI, Ratnikov B, Monosov E, Postnova TI, DiScipio R, Smith JW, Strongin AY. MT1-MMP initiates activation of pro-MMP-2 and integrin  $\alpha\beta 3$  promotes maturation of MMP-2 in breast carcinoma cells. *Exp Cell Res* **2001**; 263: 209-223.
- DiGirolamo** N, Visvanathan K, Lloyd A, Wakefield D. Expression of TNF-alpha by human plasma cells in chronic inflammation. *J Leukoc Biol* **1997**; 61: 667-678.
- DiGirolamo** N, Tedla N, Lloyd A, Wakefield D. Expression of matrix metalloproteinases by human plasma cells and B lymphocytes. *Eur J Immunol* **1998**; 28: 1773-1784.
- Ding** Y, Uitto V-J, Firth J, Salo T, Haapasalo M, Konttinen YT, Sorsa T. Modulation of host matrix metalloproteinases by bacterial virulence factors relevant in human periodontal diseases. *Oral Dis* **1995**; 1: 279-286.
- Ding** Y, Uitto VJ, Haapasalo M, Lounatmaa K, Konttinen YT, Salo T, Grenier D, Sorsa T. Membrane components of *Treponema denticola* trigger proteinase release from human polymorphonuclear leukocytes. *J Dent Res* **1996**; 75: 1986-1993.
- Ding** Y, Haapasalo M, Kerosuo E, Lounatmaa K, Kotiranta A, Sorsa T. Release and activation of human neutrophil matrix metallo- and serine proteinases during phagocytosis of *Fusobacterium nucleatum*, *Porphyromonas gingivalis* and *Treponema denticola*. *J Clin Periodontol* **1997**; 24: 237-248.
- D'Ortho** MP, Will H, Atkinson S, Butler G, Messent A, Gavrilovic J, Smith B, Timpl R, Zardi L, Murphy G. Membrane type matrix metalloproteinases 1 and 2 exhibit broad-spectrum proteolytic capacities comparable to many matrix metalloproteinases. *Eur J Biochem* **1997**; 250: 751-757.
- Edwards** DR, Beaudry PP, Laing TD, Kowal V, Leco KJ, Leco PA, Lim MS. The roles of tissue inhibitors of metalloproteinases in tissue remodelling and cell growth. *Int J Obes Relat MetabDisord* **1996**; 20 (suppl 3): S9-S15.
- Formigli** L, Orlandini S, Tonelli P, Giannelli M, Martinin M, Brandi ML, Bergamini M, Orlandini GE. Osteolytic processes in human radicular cysts: morphological and biochemical results. *J Oral Pathol Med* **1995**; 24: 216-220.
- Fouad** AF. Molecular mediators of Pulpal inflammation. In Hargreaves KM, Goodis HE editors. Seltzer and Bender's Dental pulp. Quintessence Publishing Co, Inc. **2002**; pp 247-279.
- Freije** JM, Díez-Itza I, Balbin M, Sanchez LM, Blasco R, Tolivia J, Lopez-Otin C. Molecular cloning and expression of collagenase-3, a novel human matrix metalloproteinase produced by breast carcinomas. *J Biol Chem* **1994**; 269: 16766-16773.
- Gendron** R, Grenier D, Sorsa T, Mayrand D. Inhibition of the activities of matrix metalloproteinases -2, -8 and -9 by chlorhexidine. *Clin Diagn Lab Immunol* **1999**; 6: 437-439.
- Giamberti** TA, Grant GM, Taylor GP, Hay RJ, Maher VM, McCormick JJ, Klebe RJ. Overview of matrix metalloproteinases expression in cultured human cells. *Matrix Biol* **1998**; 16: 483-496.
- Giannelli** G, Falk-Marzillier J, Schiraldi O, Stetler-Stevenson WG, Quaranta V: Induction of cell migration by matrix metalloproteinase-2 cleavage of laminin-5. *Science* **1997**; 277: 225-228.
- Giannelli** G, Pozzi A, Stetler-Stevenson W, Gardner H, Quaranta V: Expression of Matrix metalloproteinase-2 cleaved laminin-5 in breast remodelling stimulated by sex steroids. *Am J Pathol* **1999**; 154: 1193-1201.
- Gilles** C, Polette M, Coraux C, Tournier JM, Meneguzzi G, Munaut C, Volders L, Rousselle P, Birembaut P, Foidart JM. Contribution of MT1-MMP and of human laminin-5  $\gamma 2$  chain degradation to mammary epithelial cell migration. *J Cell Sci* **2001**; 114: 2967-2976.

- Goetzl EJ**, Banda MJ, Leppert D. Matrix metalloproteinases in immunity. *J Immunol* **1996**; 156: 1-4.
- Goldberg GI**, Wilhelm SM, Kronberger A, Bauer EA, Grant GA, Eisen AZ. Human fibroblast collagenase. Complete primary structure and homology to an oncogene transformation-induced rat protein. *J Biol Chem* **1986**; 261: 6600-6605.
- Goldberg GI**, Marmer BL, Grant GA, Eisen AZ, Wilhelm S, He CS. Human 72-kilodalton type IV collagenase forms a complex with a tissue inhibitor of metalloproteinases designated TIMP-2. *Proc Natl Acad Sci USA* **1989**; 86: 8207-8211.
- Golub LM**, Sorsa T, Lee HM, Ciancio S, Sorbi D, Ramamurthy NS, Gruber B, Salo T, Konttinen YT. Doxycycline inhibits neutrophil (PMN)-type matrix metalloproteinases in human adult periodontitis gingiva. *J Clin Periodontol* **1995**; 22: 100-109.
- Golub LM**, Lee HM, Greenwald RA, Ryan ME, Sorsa T, Salo T, Giannobile WV. A matrix metalloproteinase inhibitor reduces bone-type collagen degradation fragments and specific collagenases in gingival crevicular fluid during adult periodontitis. *Inflamm Res* **1997**; 46: 310-319.
- Golub LM**, Lee HM, Ryan ME, Giannobile WV, Payne J, Sorsa T. Tetracyclines inhibit connective tissue breakdown by multiple non-antimicrobial mechanisms. *Adv Dent Res* **1998**; 12: 12-26.
- Gu Y**, Lee HM, Roemer EJ, Musacchia L, Golub LM, Simon SR. Inhibition of tumor cell invasiveness by chemically modified tetracyclines. *Curr Med Chem* **2001**; 8: 261-270.
- Gutman A**, Waslyk B. The collagenase gene promoter contains a TPA and oncogene-responsive unit encompassing the PEA3 and AP-1 binding sites. *EMBO J* **1990**; 9: 2241-2246.
- Haapasalo M**. Bacteroides spp. In dental root canal infections. *Endod Dent Traumatol* **1989**; 5: 1-10.
- Haapasalo M**. Käytännön juurihoito. kerava, Finland: RT-Print; **1998**.
- Hanemaaijer R**, Sorsa T, Konttinen YT, Ding Y, Sutinen M, Visser H, van Hinsbergh VW, Helaakoski T, Kainulainen T, Rönkä H, Tschesche H, Salo T. Matrix metalloproteinase-8 is expressed in rheumatoid synovial fibroblasts and endothelial cells. Regulation by tumor necrosis factor- alpha and doxycycline. *J Biol Chem* **1997**; 272: 31504-31509.
- Hasty KA**, Jeffrey JJ, Hibbs MS, Welgus HG. The collagen substrate specificity of human neutrophil collagenase. *J Biol Chem* **1987**; 21: 10048-10052.
- Hasty KA**, Pourmotabbed TF, Goldberg GI, Thompson JP, Spinella DG, Stevens RM, Mainardi CL. Human neutrophil collagenase. A distinct gene product with homology to other matrix metalloproteinases. *J Biol Chem* **1990**; 265: 11421-11424.
- Hayakawa T**, Yamashita K, Tanzawa K, Uchijima E, Iwata K. Growth- promoting activity of tissue inhibitor of metalloproteinases-1 (TIMP-1) for a wide range of cells. A possible new growth factor in serum. *FEBS Lett* **1992**; 298: 29-32.
- Hayakawa T**, Yamashita K, Ohuchi E, Shinagawa A. Cell growth-promoting activity of tissue inhibitor of metalloproteinase-2 (TIMP-2). *J Cell Sci* **1994**; 107: 2373-2379.
- Heikkilä P**, Teronen O, Moilanen M, Konttinen YT, Hanemaaijer R, Laitinen M, Maisi P, van der Pluijm G, Bartlett JD, Salo T, Sorsa T. Bisphosphonates inhibit stromelysin-1 (MMP-3), matrix metalloelastase (MMP- 12), collagenase-3 (MMP-13) and enamelysin (MMP-20), but not urokinase-type plasminogen activator, and diminish invasion and migration of human malignant and endothelial cell lines. *Anticancer Drugs* **2002**; 13: 245-254.
- Heikkilä P**, Teronen O, Hirn MY, Sorsa T, Tervahartiala T, Salo T, Konttinen YT, Halttunen T, Moilanen M, Hanemaaijer R, Laitinen M. Inhibition of matrix metalloproteinase-14 in osteosarcoma cells by clodronate. *J Surg Res* **2003**; 111: 45-52.
- Hirshberg A**, Sherman S, Buchner A, Dayan D. Collagen fibres in the wall of odontogenic keratocysts: a study with picosirius red and polarizing microscopy. *J Oral Pathol Med* **1999**; 28: 410-412.
- Hoenig JF**, Rordorf-Adam C, Siegmund C, Erard F. Measurement of interleukin 1 alpha and beta (IL-1 alpha and IL-1 beta) in human cystic lesions of the jaw. Implications for the pathogenesis of radicular cysts. *Bull Group Int Rech Sci Stomatol Odontol* **1991**; 34: 67-72.
- Hofmann UB**, Westphal JR, van Muijen GN, Rüter D. Matrix metalloproteinases in human melanoma. *J Invest Dermatol* **2000**; 115: 337-344.
- Holliday LS**, Welgus HG, Fliszar CJ, Veith M, Jeffrey JJ, Gluck SL. Initiation of osteoclasts bone resorption by interstitial collagenase. *J Biol Chem* **1997**; 35: 22053-220589.
- Holopainen J**, Moilanen J, Sorsa T, Kivela-Rajamäki M, Tervahartiala T, Vesaluoma M, Tervo T. Activation of matrix metalloproteinase-8 by membrane type 1-MMP and their expression in human tears after photorefractive keratectomy. *Invest Ophthalmol Vis Sci* **2003**; 44: 2550-2556.
- Horiba N**, Maekawa Y, Abe Y, Ito M, Matsumoto T, Nakamura H. Correlations between endotoxin and clinical symptoms or radiolucent areas in infected root canals. *Oral Surg Oral Med Oral Pathol* **1991**; 71: 492-495.
- Hoshino M**, Nakamura Y, Sim J, Shimojo J, Isogai S. Bronchial subepithelial fibrosis and xpression of matrix metalloproteinase-9 in asthmatic airway inflammation. *J Allergy Clin Immunol* **1998**; 102: 783-788.
- Huhtala P**, Chow LT, Tryggvason K. Structure of the human type IV collagenase gene. *J Biol Chem* **1990**; 265:

11077-11082.

- Ingman T**, Tervahartiala T, Ding Y, Tschesche H, Haerian T, Kinane DF, Konttinen YT, Sorsa T. Matrix metalloproteinases and their inhibitors in gingival crevicular fluid and saliva of periodontitis patients. *J Clin Periodontol* **1996**; 23: 1127-1132.
- Ito A**, Mukaiyama A, Itoh Y, Nagase H, Thogersen IB, Enghild JJ, Sasaguri Y, Mori Y. Degradation of interleukin 1 IL-1 $\beta$  by matrix metalloproteinases. *J Biol Chem* **1996**; 271: 14657-14660.
- Jaffe ES**, Harris NL, Stein H, Wardi JW. WHO classification of tumours, pathology and genetics, tumour of haematopoietic and lymphoid tissues. IARC-Press, Lyon, France. **2001**.
- Johansson N**, Airola K, Grenman R, Kariniemi AL, Saarialho-Kere U, Kähäri VM. Expression of collagenase-3 (matrix metalloproteinase-13) in squamous cell carcinomas of the head and neck. *Am J Pathol* **1997a**; 151: 499-508.
- Johansson N**, Westermarck KJ, Leppä S, Häkkinen L, Koivisto L, Lopez-Otin C, Peltonen J, Heino J, Kähäri VM. Collagenase 3 (Matrix metalloproteinase 13) gene expression by HaCaT keratinocytes is enhanced by tumor necrosis factor alpha and transforming growth factor beta. *Cell Growth & Different* **1997b**; 8: 243-250.
- Johansson N**, Ahonen M, Kähäri VM. Matrix metalloproteinases in tumor invasion. *Cell Mol Life Sci* **2000**; 57: 5-15.
- Kähäri VM**, Saarialho-Kere U. Matrix metalloproteinases and their inhibitors in tumour growth and invasion. *Ann Med* **1999**; 31: 34-35.
- Kallunki P**, Sainio K, Eddy R, Byers M, Kallunki T, Sariola H, Beck K, Hirvonen H, Shows TB, Tryggvason K. A truncated laminin chain homologous to the B2 chain: structure, spatial expression, and chromosomal assignment. *J Cell Biol* **1992**; 119: 679-693.
- Kerr LD**, Miller DB, Matrisian LM. TGF- $\beta$ 1 inhibition of transin/stromelysin gene expression is mediated through a Fos binding sequence. *Cell* **1990**; 61: 267-278.
- Khokha R**, Waterhouse P, Yagel S, Lala PK, Overall CM, Norton G, Denhardt DT. Antisense RNA-induced reduction in murine TIMP-levels confers oncogenicity on Swiss 3T3 cells. *Science* **1989**; 243: 947-950.
- Kivela-Rajamäki M**, Teronen O, Maisi P, Husa V, Tervahartiala T, Piriä E, Salo T, Mellanen L, Sorsa T. Laminin -5  $\gamma$ 2-chain and collagenase-2 (MMP-8) in human peri-implant sulcular fluid. *Clin Oral Impl Res* **2003**; 14: 158-165.
- Knäuper V**, López-Otín C, Smith B, Knight G, Murphy G. Biochemical characterization of human collagenase-3. *J Biol Chem* **1996a**; 271: 1544-1550.
- Knäuper V**, Will H, López-Otín C, Smith B, Atkinson SJ, Stanton H, Hembry RM, Murphy G. Cellular mechanism for human procollagenase-3 activation. Evidence that MT1-MMP (MMP-14) and gelatinase A (MMP-2) are able to generate active enzyme. *J Biol Chem* **1996b**; 271: 17124-17131.
- Knäuper V**, Smith B, López-Otín C, Murphy G. Activation of progelatinase B (proMMP-9) by active collagenase-3 (MMP-13). *Eur J Biochem* **1997**; 248: 369-373.
- Kiili M**, Cox SW, Chen HW, Wahlgren J, Maisi P, Eley BM, Salo T, Sorsa T. Collagenase-8 (MMP-8) and collagenase-3 (MMP-13) in adult periodontitis: molecular forms and levels in gingival crevicular fluid and immunolocalization in gingival tissue. *J Clin Periodontol* **2002**; 29: 224-232.
- Koivunen E**, Arap W, Valtanen H, Rainisalo A, Medina O, Heikkilä P, Kantor C, Gahmberg C, Salo T, Konttinen YT, Sorsa T, Ruoslahti E, Pasqualini R. Tumor targeting with a selective gelatinase inhibitor. *Nat Biotechnol* **1999**; 17: 768-774.
- Konttinen YT**, Lindy O, Kempainen P, Saari H, Suomalainen K, Vauhkonen M, Lindy S, Sorsa T. Collagenase reserves in polymorphonuclear neutrophil leukocytes from synovial fluid and peripheral blood of patients with rheumatoid arthritis. *Matrix* **1991**; 11: 296-301.
- Konttinen YT**, Ceponis A, Takagi M, Ainola M, Sutinen M, Sorsa T, Salo T, Ma J, Santavirta S, Seiki M. New collagenolytic enzymes/cascade identified at the pannus-hard tissue junction in rheumatoid arthritis: destruction from above. *Matrix Biol* **1998**; 17: 585-601.
- Koshikawa N**, Giannelli G, Cirulli V, Miyazaki K, Quaranta V. Role of cell surface metalloprotease MT1-MMP in epithelial cell migration over laminin-5. *J Cell Biol* **2000**; 148: 3: 615-624.
- Kramer IRH**. Changing views on oral disease. *Proc R Soc Med* **1974**; 67: 271-276.
- Kramer IRH**, Pindborg JJ, Shear M. Histological typing of odontogenic tumours, 2nd ed, Berlin: Springer-Verlag, **1992**: 35-41.
- Kubota Y**, Ninomiya T, Oka S, Takenoshita Y, Shirasuna K. Interleukin-1 $\alpha$ -dependent regulation of matrix metalloproteinase-9 (MMP-9) secretion and activation in the epithelial cells of odontogenic jaw cysts. *J Dent Res* **2000**; 79: 1423-1430.
- Kubota Y**, Oka S, Nakagawa S, Shirasuna K. Interleukin 1- $\alpha$  enhances type I collagen-induced activation of matrix metalloproteinase-2 in odontogenic keratocyst fibroblasts. *J Dent Res* **2002**; 81: 23-27.
- Lanone S**, Zheng T, Zhu Z, Liu W, Lee CG, Ma B, Chen Q, Homer RJ, Wang J, Rabach LA, Rabach ME, Shipley JM, Shapiro SD, Senior RM, Elias JA. Overlapping and enzyme-specific contributions of matrix metalloproteinases-9 and -12 in IL-13-induced inflammation and remodelling. *J Clin Invest* **2002**; 110: 463-

474.

- Lauta VM.** Interleukin-6 and the network of several cytokines in multiple myeloma: an overview of clinical and experimental data. *Cytokine* **2001**; 16: 79-86.
- Leco KJ, Khokha R, Pavloff N, Hawkes SP, Edwards DR.** Tissue inhibitor of metalloproteinase-3 (TIMP-3) is an extracellular matrix-associated protein with a distinctive pattern of expression in mouse cells and tissue. *J Biol Chem* **1994**; 269: 9352-9360.
- Lerner UH.** Regulation of bone metabolism by the kallikrein-kinin system, the coagulation cascade, and the acute-phase reactants. *Oral Surg Oral Med Oral Pathol* **1994**; 78: 481-493.
- Lesot H, Smith AJ, Tziafas D, Begue-Kirn C, Cassidy N, Ruch JV.** Biologically active molecules and dental tissue repair: a comparative review of reactionary and reparative dentinogenesis with the induction of odontoblast differentiation *in vitro*. *Cells Mater* **1994**; 4: 199-218.
- Li TJ, Browne RM, Matthews JB.** Quantification of PCNA+ cells within odontogenic jaw cyst epithelium. *J Oral Pathol Med* **1994**; 23: 184-189.
- Li T, Browne RM, Matthes JB.** Immunocytochemical expression of growth factors by odontogenic jaw cysts. *Mol Pathol* **1997**; 50: 21-27.
- Lin SK, Chiang CP, Hong CY, Lin CP, Lan WH, Hsieh CC, Kuo MY.** Immunolocalization of interstitial collagenase (MMP-1) and tissue inhibitor of metalloproteinases-1 (TIMP-1) in radicular cysts. *J Oral Pathol Med* **1997**; 26: 458-463.
- Lin SK, Wang CC, Huang S, Lee JJ, Chiang CP, Lan WH, Hong CY.** Induction of Dental pulp fibroblast matrix metalloproteinases-1 and tissue inhibitor of metalloproteinases-1 gene expression by interleukin-1 $\alpha$  and tumor necrosis factor- $\alpha$  through a prostaglandin-dependent pathway. *J Endod* **2001**; 27: 185-189.
- Lindy O, Kontinen YT, Sorsa T, Ding Y, Santavirta S, Ceponis A, López-Otín C.** Matrix metalloproteinase 13 (collagenase 3) in human rheumatoid synovium. *Arthritis Rheum* **1997**; 40: 1391-1399.
- Liu Y, Ryan M, Lee H-M, Sorsa T, Salo T, Tjäderhane L, Walker S, Golub L.** A chemically modified tetracycline (CMT-3) inhibits a metalloproteinase of *C. Albicans*. *J Dent Res (Spec Iss A)* **2002**; 81: A-284.
- Llano E, Pendas AM, Knäuper V, Sorsa T, Salo T, Salido E, Murphy G, Simmer JP, Bartlett JD, Lopez-Otin C.** Identification and structural and functional characterization of human enamelysin (MMP-20). *Biochemistry* **1997**; 36: 15101-15108.
- Llavaneras A, Golub LM, Rifkin BR, Heikkilä P, Sorsa T, Teronen O, Salo T, Liu Y, Ryan ME, Ramamurthy NS.** CMT-8/clondronate combination therapy synergistically inhibits alveolar bone loss in LPS-induced periodontitis. *Ann N Y Acad Sci* **1999**; 878: 671-674.
- Llavaneras A, Ramamurthy NS, Heikkilä P, Teronen O, Salo T, Rifkin BR, Ryan ME, Golub LM, Sorsa T.** A combination of a chemically modified doxycycline and a bisphosphonate synergistically inhibits endotoxin-induced periodontal breakdown in rats. *J Periodontol* **2001**; 72: 1069-1077.
- Lohi J.** Laminin-5 in the progression of carcinomas. *Int J Cancer* **2001**; 94: 763-767.
- Lohi J, Wilson CL, Roby JD, Parks WC.** Epilysin, a novel human matrix metalloproteinase (MMP-28) expressed in testis and keratinocytes and in response to injury. *J Biol Chem* **2001**; 276: 10134-10144.
- Lokeshwar BL, Selzer MG, Zhu BQ, Block NL, Golub LM.** Inhibition of cell proliferation, invasion, tumor growth and metastasis by an oral non-antimicrobial tetracycline analog (COL-3) in a metastatic prostate cancer model. *Int J Cancer* **2002**; 98: 297-309.
- Lu HX, Xiao MZ, Niu XY, Guo XM, Zhao SL, Wang HG, Guo HY.** Effect of IL-1ra on human dental pulp cells and pulpal inflammation. *Int Endod J* **2002**; 35: 807-811.
- Lukinmaa PL, Vaahtokari A, Vainio S, Thesleff I.** Expression of the type I collagen pro- $\alpha$  2 chain mRNA in adult human permanent teeth as revealed by *in situ* hybridization. *J Dent Res* **1992**; 71: 36-42.
- Lukinmaa PL, Vaahtokari A, Vainio S, Sandberg M, Waltimo J, Thesleff I.** Transient expression of type III collagen by odontoblasts: developmental changes in the distribution of pro- $\alpha$  1(III) and pro- $\alpha$  1(I) collagen mRNAs in dental tissues. *Matrix* **1993**; 13: 503-515.
- Lukkonen A, Sorsa T, Salo T, Tervahartiala T, Koivunen E, Golub L, Simon S, Stenman U-H.** Down-regulation of trypsinogen-2 expression by chemically modified tetracyclines: association with reduced cancer cell migration. *Int J Cancer* **2000**; 86: 577-581.
- Mäkelä M, Larjava H, Pirilä E, Maisi P, Salo T, Sorsa T, Uitto VJ.** Matrix metalloproteinase-2 (gelatinase-A) is related to migration of keratinocytes. *Exp Cell Res* **1999**; 251: 67-78.
- Mäntylä P, Kinane D, Luoto S, Tikanoja S, Sorsa T.** MMP (matrix metalloproteinase) –8 in monitoring periodontal health and disease from gingival crevicular fluid (GCF). *J Clin Periodontol* **2000**; 27 (suppl 1): 97.
- Mäntylä P, Stenman M, Kinane D, Tikanoja S, Luoto H, Salo T, Sorsa T.** Gingival crevicular fluid collagenase-2 (MMP-8) test stick for chair-side monitoring of periodontitis. *J Periodontal Res* **2003**; 38: 436-439.
- Marchenko GN, Ratnikov BI, Rozanov DV, Godzik A, Deryugina EI, Strongin AY.** Characterization of matrix metalloproteinase-26, a novel metalloproteinase widely expressed in cancer cells of epithelial origin. *Biochem J* **2001**; 356: 705-718.
- Marchenko GN, Strongin AY.** MMP-28, a new human matrix metalloproteinase with an unusual cysteine-

- switch sequence is widely expressed in tumors. *Gene* **2001**; 265: 87-93.
- Marton IJ, Kiss C.** Protective and destructive immune reactions in apical periodontitis. *Oral Microbiol Immunol* **2000**; 15: 139-150.
- Matsuo T, Nakanishi T, Ebisu S.** Immunoglobulins in periapical exudates of infected root canals: correlations with the clinical findings of the involved teeth. *Endod Dent Traumatol* **1995**; 11: 95-99.
- Matthes T, Werner-Favre C, Zubler RH.** Cytokine expression and regulation of human plasma cells: disappearance of interleukin-10 and persistence of transforming growth factor- $\beta$ 1. *Eur J Immunol* **1995**; 25: 508-512.
- Matthews JB, Mason GI, Browne RM.** Epithelial cell markers and proliferating cells in odontogenic jaw cysts. *J Pathol* **1988**; 156: 283-290.
- Mautino G, Oliver N, Chanez P, Bousquet J, Capony F.** Increased release of matrix metalloproteinase-9 in bronchoalveolar lavage fluid and by alveolar macrophages of asthmatics. *Am J Respir Cell Mol Biol* **1997**; 17: 583-591.
- McClanahan SB, Turner DW, Kaminski EJ, Osetek EM, Heuer M.** Natural modifiers of the inflammatory process in the human dental pulp. *J Endod* **1991**; 17: 589-593.
- Meikle MC, Bord S, Hembry RM, Comston J, Croucher PI, Reynolds JJ.** Human osteoblasts in culture synthesize collagenase and other matrix metalloproteinases in response to osteotropic hormones and cytokines. *J Cell Sci* **1992**; 103: 1093-1099.
- Meghji S, Henderson B, Bando Y, Harris M.** Interleukin-1: the principal osteolytic cytokine produced by keratocysts. *Arch Oral Biol* **1992**; 37: 935-943.
- Meghji S, Qureshi W, Henderson B, Harris M.** The role of endotoxin and cytokines in the pathogenesis of odontogenic cysts. *Arch Oral Biol* **1996**; 41: 523-31.
- Merville P, Dechanet J, Grouard G, Durand I, Banchereau J.** T cell-induced B cell blasts differentiate into plasma cells when cultured on bone marrow stroma with IL-3 and IL-10. *Int Immunol* **1995**; 7: 635-643.
- Metzger Z.** Macrophages in periapical lesions. *Endod Dent Traumatol* **2000**; 16: 1-8.
- Michaelis J, Vissers MC, Winterbourn CC.** Human neutrophil collagenase cleaves  $\alpha_1$ -antitrypsin. *Biochem J* **1990**; 270: 809-814.
- Miller GA, DeMayo T, Hutter JW.** Production of interleukin-1 by polymorphonuclear leucocytes resident in periradicular tissue. *J Endod* **1996**; 22: 346-351.
- Mirastschijski U, Impola U, Jahkola T, Karlsmark T, Agren MS, Saarialho-Kere U.** Ectopic localization of matrix metalloproteinase-9 in chronic cutaneous wounds. *Hum Pathol* **2002**; 33: 355-364.
- Mitchell PG, Magna HA, Reeves LM, Lopresti-Morrow LL, Yocum SA, Rosner PJ, Geoghegan KF, Hambor JE.** Cloning, expression, and type II collagenolytic activity of matrix metalloproteinase-13 from human osteoarthritic cartilage. *J Clin Invest* **1996**; 97: 761-768.
- Miyauchi M, Takata T, Ito H, Ogawa I, Kobayashi J, Nikai H, Ijuhin N.** Immunohistochemical detection of prostaglandins  $E_2$ ,  $F_{2\alpha}$ , and 6-ketoprostaglandin  $F_{1\alpha}$  in experimentally induced periapical inflammatory lesions in rats. *J Endod* **1996**; 22: 635-637.
- Moilanen M, Sorsa T, Stenman M, Nyberg P, Lindy O, Vesterinen J, Paju A, Kontinen YT, Stenman U-H, Salo T.** Tumor-associated trypsinogen-2 (trypsinogen-2) activates procollagenases (MMP-1, -8, -13) and stromelysin-1 (MMP-3) and degrades type I collagen. *Biochemistry* **2003**; 42: 5414-5420.
- Morand MA, Schilder H, Blondin J, Stone PJ, Franzblau C.** Collagenolytic and elastinolytic activities from diseased human dental pulps. *J Endod* **1981**; 7: 156-160.
- Myoung H, Hong S-P, Hong S-D, Lee J-I, Lim C-Y, Choung P-H, Lee J-H, Choi J-Y, Seo B-M, Kim M-J.** Odontogenic keratocyst: Review of 256 cases for recurrence and clinicopathologic parameters. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod* **2001**; 91: 328-333.
- Nakanishi T, Matsuo T, Ebisu S.** Quantitative analysis of immunoglobulins and inflammatory factors in human pulpal blood from exposed pulps. *J Endod* **1995**; 21: 999-1003.
- Nakano A, Tani E, Miyazaki K, Furuyama J, Matsumoto T.** Expression of matrilysin and stromelysin in human glioma cells. *Biochem Biophys Res Commun* **1993**; 192: 237-244.
- Nakata K, Yamasaki M, Iwata T, Suzuki K, Nakane A, Nakamura H.** Anaerobic bacterial extracts influence production of matrix metalloproteinases and their inhibitors by human dental pulp cells. *J Endod* **2000**; 26: 410-413.
- Neville BW, Damm DD, Allen CM, Bouquot JE.** Oral & Maxillofacial Pathology. Philadelphia, USA: WB Saunders Co **2002**; pp 107-136, 589-601.
- Nisengard R, Newman M.** Oral microbiology and immunology, second edition. Philadelphia, USA: W.B. Saunders Co **1994**; pp 8-10.
- Nyberg P, Moilanen M, Paju A, Sarin A, Stenman UH, Sorsa T, Salo T.** MMP-9 activation by tumor trypsin-2 enhances *in vivo* invasion of human tongue carcinoma cells. *J Dent Res* **2002**; 81: 831-835.
- O'Boskey FJ Jr, Panagakos F.** Cytokines stimulate matrix metalloproteinase production by human pulp cells during long-term culture. *J Endod* **1998**; 24: 7-10.

- Okiji T.** Pulp as a connective tissue. In: Hargreaves KM, Goodis HE editors. Seltzer and Bender's Dental pulp. Quintessence Publishing Co, Inc. **2002**; pp 95-122.
- Overall CM, Wrana JL, Sodek J.** Transcriptional and post-transcriptional regulation of 72-kDa elatinase/type IV collagenase by transforming growth factor- $\beta$ 1 in human fibroblasts. Comparisons with collagenase and tissue inhibitor of matrix metalloproteinase gene expression. *J Biol Chem* **1991**; 266: 14064-14071.
- Palosaari H, Tasanen K, Risteli J, Larmas M, Salo T, Tjäderhane L.** Baseline expression and effect of TGF-beta1 on type I and III collagen mRNA and protein synthesis in human odontoblast and pulp cells in vitro. *Calcif Tissue Int* **2001**; 68: 122-129.
- Palosaari H, Ding Y, Larmas M, Sorsa T, Bartlett JD, Salo T, Tjäderhane L.** Regulation and interactions of MT1-MMP and MMP-20 in human odontoblasts and pulp tissue in vitro. *J Dent Res* **2002**; 81: 354-359.
- Panagakos FS, O'Boskey JF Jr, Rodriguez E.** Regulation of pulp cell matrix metalloproteinase production by cytokines and lipopolysaccharides. *J Endod* **1996**; 22: 358-361.
- Patel V, Aldridge K, Ensley JF, Odell E, Boyd A, Jones J, Gutkind JS, Yeudall WA.** Laminin- $\gamma$ 2 overexpression in head-and-neck squamous cell carcinoma. *Int J Cancer* **2002**; 99: 583-588.
- Pattengale PK.** Role of interleukin-6 in the pathogenesis of murine plasmacytoma and human multiple myeloma. *Am J Pathol* **1997**; 151: 647-649.
- Pei D, Weiss SJ.** Furin-dependent intracellular activation of the human stromelysin-3 zymogen. *Nature* **1995**; 375: 244-247.
- Peled ZM, Phelps ED, Updike DL, Chang J, Krummel TM, Howard EW, Longaker MT.** Matrix metalloproteinases and the ntogeny of scarless repair: The other side of the wound healing balance. *Plast Reconstr Surg* **2002**; 110: 801-811.
- Piattelli A, Artese L, Rosini S, Quaranta M, Musiani P.** Immune cells in periapical granuloma: morphological and immunohistochemical characterization. *J Endod* **1991**; 17: 26-29.
- Piattelli A, Fioroni M, Santinelli A, Rubini C.** P53 protein expression in odontogenic cysts. *J Endod* **2001**; 27: 459-461.
- Pirilä E, Ramamurthy N, Maisi P, WcClain S, Kucine A, Wahlgren J, Golub L, Salo T, Sorsa T.** Wound healing in ovariectomized rats. Effects of chemically modified tetracycline (CMT-8) and estrogen on matrix metalloproteinases -8, -13 and type I collagen expression. *Curr Med Chem* **2001a**; 7: 281-294.
- Pirilä E, Maisi P, Salo T, Koivunen E, Sorsa T.** In vivo localization of gelatinases (MMP-2 and MMP-9) by in situ zymography with a selective gelatinase inhibitor. *Biochem Biophys Res Commun* **2001b**; 287: 766-774.
- Pirilä E, Sharabi A, Salo T, Quaranta V, Tu H, Heljasvaara R, Koshikawa N, Sorsa T, Maisi P.** Matrix metalloproteinases process laminin-5  $\gamma$ 2-chain and regulate epithelial cell migration. *Biochem Biophys Res Commun* **2003**; 303: 1012-1017.
- Poulsom R, Pignatelli M, Stetler-Stevenson WG, Liotta LA, Wright PA, Jeffery RE, Longcroft JM, Rogers L, Stamp GW.** Stromal expression of 72-kda type IV collagenase (MMP-2) and TIMP-2 mRNAs in colonrectal neoplasia. *Am J Pathol* **1992**; 141: 389-396.
- Prikk K, Maisi P, Pirilä E, Sepper R, Salo T, Wahlgren J, Sorsa T.** In vivo collagenase-2 (MMP-8) expression by human bronchial epithelial cells and monocytes/macrophages in bronchiectasis. *J Pathol* **2001**; 194: 232-238.
- Prikk K, Maisi P, Pirilä E, Reintam MA, Salo T, Sorsa T, Sepper R.** Airway obstruction correlates with collagenase-2 (MMP-8) expression and activation in bronchial asthma. *Lab Invest* **2002**; 82:1535-1545.
- Pulkkinen L, Christiano AM, Airene T, Haakana H, Tryggvason K, Uitto J.** Mutations in the  $\gamma$ 2 chain gene- (LAMC2) of kalinin/laminin 5 in the junctional forms of epidermolysis bullosa. *Nature Genet* **1994**; 6: 293-297.
- Ramamurthy NS, Rifkin BR, Greenwald RA, Xu JW, Liu Y, Turner G, Golub LM, Vernillo AT.** Inhibition of matrix metalloproteinase-mediated periodontal bone loss in rats: a comparison of 6 chemically modifies tetracyclines. *J Periodontol* **2002**; 73: 726-734.
- Ravanti L, Häkkinen L, Larjava H, Saarialho-Kere, Foschi M, Han J, Kähäri VM.** Transforming growth factor- $\beta$  induces collagenase-3 expression by human gingival fibroblasts via p38 mitogen-activated protein kinase. *J Biol Chem* **1999**; 274: 37292-37300.
- Regezi JA.** Odontogenic cysts, odontogenic tumors, fibrousseus, and giant cell lesions of the jaws. *Mod Pathol* **2002**; 15: 331-341.
- Reponen P, Sahlberg C, Munaut C, Thessleff I, Tryggvason K.** High expression of 92 -kD type IV collagenase (gelatinase B) in the osteoclast lineage during mouse development. *J Cell Biol* **1994**; 124: 1091-1102.
- Ria R, Vacca A, Ribatti D, Di Raimondo F, Merchionne F, Dammacco F.**  $\alpha_v\beta_3$  integrin engagement enhances cell invasiveness in human multiple myeloma. *Haematologica* **2002**; 87: 836-845.
- Rifas L, Halstead LR, Peck WA, Avioli LV, Welgus HG.** Human osteoblasts *in vitro* secrete tissue inhibitor of metalloproteinases and gelatinase but not interstitial collagenase as major products. *J Clin Invest* **1989**; 84: 692-694.
- Ross MH, Reith EJ, Romrell LJ.** *Histology: a text and atlas*, 2<sup>nd</sup> ed. Baltimore, MD: Williams and Wilkins cop,

- 1989; 309-311.
- Rousset F, Peyrol S, Garcia E, Vezzio N, Andujar M, Grimaud JA, Banchereau J.** Long-term cultured CD40-activated B lymphocytes differentiate into plasma cells in response to IL-10 but not IL-4. *Int Immunol* **1995**; 7: 1243-1253.
- Rousselle P, Keene DR, Ruggiero F, Champliand MF, Rest M, Burgeson RE.** Laminin 5 binds to the NC-1 domain of type VII collagen. *J Cell Biol* **1997**; 138: 719-728.
- Saarialho-Kere UK, Chang ES, Welgus HG, Parks WC.** Distinct localization of collagenase and tissue inhibitor of metalloproteinases expression in wound healing associated with ulcerative pyogenic granuloma. *J Clin Invest* **1992**; 90: 1952-1957.
- Saarialho-Kere UK, Welgus HG, Parks WC.** Distinct mechanisms regulate interstitial collagenase and 92-kDa gelatinase expression in human monocytic-like cells exposed to bacterial endotoxin. *J Biol Chem* **1993**; 268: 17354-17361.
- Saarialho-Kere UK, Vaalamo M, Airola K, Niemi KM, Oikarinen AI, Parks WC.** Interstitial collagenase is expressed by keratinocytes that are actively involved in reepithelialization in blistering skin diseases. *J Invest Dermatol* **1995**; 104: 982-988.
- Salo S, Haakana H, Kontusaari S, Hujanen E, Kallunki T, Tryggvason K.** Laminin-5 promotes adhesion and migration of epithelial cells: identification of a migration-related element in the  $\gamma 2$  chain gene (LAMC2) with activity in transgenic mice. *Matrix Biol* **1999**; 18: 197-210.
- Salo T, Liotta LA, Tryggvason K.** Purification and characterization of a murine basement membrane collagen-degrading enzyme secreted by metastatic tumor cells. *J Biol Chem* **1983**; 258: 3058-63.
- Salo T, Lyons JG, Rahemtulla F, Birkedal-Hansen H, Larjava H.** Transforming growth factor- $\beta 1$  up-regulates type IV collagenase expression in cultured human keratinocytes. *J Biol Chem* **1991**; 266: 11436-11441.
- Sati HI, Apperley JF, Greaves M, Lawry J, Gooding R, Russell RG, Croucher PJ.** Interleukin-6 is expressed by plasma cells from patients with multiple myeloma and monoclonal gammopathy of undetermined significance. *Br J Haematol* **1998**; 101: 287-295.
- Schönbeck U, Mach F, Libby P.** Generation of biologically active IL-1 beta by matrix metalloproteinases: a novel caspase-1-independent pathway of IL-1 beta processing. *J Immunol* **1998**; 161: 3340-3346.
- Shear M.** The aggressive nature of the odontogenic keratocyst: is it a benign cystic neoplasm? Part 1. Clinical and early experimental evidence of aggressive behaviour. *Oral Oncol* **2002a**; 38: 219-226.
- Shear M.** The aggressive nature of the odontogenic keratocyst: is it a benign cystic neoplasm? Part 2. Proliferation and genetic studies. *Oral Oncol* **2002b**; 38: 323-331.
- Shear M.** The aggressive nature of the odontogenic keratocyst: is it a benign cystic neoplasm? Part 3. Immunocytochemistry of cytokeratin and other epithelial cell markers. *Oral Oncol* **2002c**; 38: 407-415.
- Shin SJ, Lee JI, Baek SH, Lim SS.** Tissue levels of matrix metalloproteinases in pulps and periapical lesions. *J Endod* **2002**; 28: 313-315.
- Skyldberg B, Salo S, Eriksson E, Aspenblad U, Moberger B, Tryggvason K, Auer G.** Laminin-5 as a marker of invasiveness in cervical lesions. *J Natl Cancer Inst* **1999**; 91: 1882-1887.
- Soini Y, Hurskainen T, Höyhty M, Oikarinen A, Autio-Harmainen H.** 72 KD and 92 KD type IV collagenase, type IV collagen, and laminin mRNAs in breast cancer: a study by in situ hybridization. *J Histochem Cytochem* **1994**; 42: 945-951.
- Soini Y, Määttä M, Salo S, Tryggvason K, Autio-Harmainen H.** Expression of the laminin  $\gamma 2$  chain in pancreatic adenocarcinoma. *J Pathol* **1996**; 180: 290-294.
- Soini Y, Satta J, Määttä M, Autio-Harmainen H.** Expression of MMP2, MMP9, MT1-MMP, TIMP1, and TIMP2 mRNA in valvular lesions of the heart. *J Pathol* **2001**; 194: 225-231.
- Sorsa T, Ylipaavalniemi P, Suomalainen K, Vauhkonen M, Lindy S.** Type-specific degradation of interstitial collagens by human keratocyst wall collagenase. *Med Sci Res* **1988**; 16: 1189-1190.
- Sorsa T, Suomalainen K, Helenius J, Lindy S, Saari H, Konttinen YT, Uitto VJ.** Periodontal disease. (A letter). *New Engl J Med* **1990**; 323: 133-135.
- Sorsa T, Ingman T, Suomalainen K, Haapasalo M, Konttinen YT, Lindy O, Saari H, Uitto VJ.** Identification of proteases from periodontopathogenic bacteria as activators of latent human neutrophil and fibroblast-type interstitial collagenases. *Infect Immun* **1992**; 60: 4491-4495.
- Sorsa T, Ding Y, Salo T, Lauhio A, Teronen O, Ingman T, Ohtani H, Andoh N, Takeha S, Konttinen YT.** Effects of tetracyclines on neutrophil, gingival, and salivary collagenases. A functional and western-blot assessment with special reference to their cellular sources in periodontal diseases. *Ann N Y Acad Sci* **1994**; 732: 112-131.
- Sorsa T, Ding Y, Ingman T, Salo T, Westerlund U, Haapasalo M, Tschesche H, Konttinen YT.** Cellular source, activation and inhibition of dental plaque collagenase. *J Clin Periodontol* **1995**; 22: 709-717.
- Sorsa T, Salo T, Koivunen E, Tyynelä J, Konttinen YT, Bergmann U, Tuuttila A, Niemi E, Teronen O, Heikkilä P, Tschesche H, Leinonen J, Osman S, Stenman UH.** Activation of type IV procollagenases by human tumor-associated trypsin-2. *J Biol Chem* **1997**; 272: 21067-21074.
- Sorsa T, Ramamurthy NS, Vernillo AT, Zhang X, Konttinen YT, Rifkin BR, Golub LM.** Functional sites of

- chemically modified tetracyclines: inhibition of the oxidative activation of human neutrophil and chicken osteoclast pro-matrix metalloproteinases. *J Rheumatol* **1998**; 15: 975-982.
- Sorsa T**, Mäntylä P, Rönkä H, Kallio P, Kallis GB, Lundqvist C, Kinane DF, Salo T, Golub LM, Teronen O, Tikanoja S. Scientific basis of a matrix metalloproteinase-8 specific chair-side test for monitoring periodontal and peri-implant health and disease. *Ann N Y Acad Sci* **1999**; 878: 130-140.
- Stashenko P**. The role of immune cytokines in the pathogenesis of periapical lesions. *Endod Dent Traumatol* **1990**; 6: 89-96.
- Sternlicht MD**, Werb Z. How matrix metalloproteinases regulate cell behaviour. *Annu Rev Cell Dev Biol* **2001**; 17: 463-516.
- Stetler-Stevenson WG**, Kruntzsch HC, Liotta LA. Tissue inhibitor of metalloproteinase (TIMP-2). A new member of the metalloproteinase inhibitor family. *J Biol Chem* **1989**; 264: 17374-17378.
- Stetler-Stevenson WG**. Type IV collagenases in tumor invasion and metastasis. *Cancer Metastasis Rev* **1990**; 9: 289-303.
- Stetler-Stevenson M**, Mansoor A, Lim M, Fukushima P, Kehrl J, Marti G, Ptaszynski K, Wang J, Stetler-Stevenson WG. Expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases in reactive and neoplastic lymphoid cells. *Blood* **1997**; 89: 1708-1715.
- Stolow MA**, Bauzon DD, Li J, Sedgwick T, Liang VC, Sang QA, Shi YB. Identification and characterization of a novel collagenase in *Xenopus laevis*: possible roles during frog development. *Mol Biol Cell* **1996**; 7: 1471-1483.
- Stähle-Bäckdahl M**, Sandstedt B, Bruce K, Lindahl A, Jiménez MG, Vega JA, Lopéz-Otín C. Collagenase-3 (MMP-13) is expressed during human fetal ossification and re-expressed in postnatal bone remodeling and in rheumatoid arthritis. *Lab Invest* **1997**; 76: 717-728.
- Sulkala M**, Wahlgren J, Larmas M, Sorsa T, Teronen O, Salo T, Tjäderhane L. The effect of MMP activity and caries progression in rats. *J Dent Res* **2001**; 80: 1545-1549.
- Sulkala M**, Larmas M, Sorsa T, Salo T, Tjäderhane L. The localization of matrix metalloproteinase-20 (MMP-20, enamelysin) in mature human teeth. *J Dent Res* **2002**; 81: 603-607.
- Sutinen M**. Expression of MMP-2 and MMP-9 in mucocutaneous and bone lesions. Acta Universitatis Dissertation. Oulu: University of Oulu, Finland; **1998**; pp 64-66.
- Sutinen M**, Kainulainen T, Hurskainen T, Vesterlund E, Alexander JP, Overall CM, Sorsa T, Salo T. Expression of matrix metalloproteinases (MMP-1 and -2) and their inhibitors (TIMP-1, -2 and -3) in oral lichen planus, dysplasia, squamous cell carcinoma and lymph node metastasis. *Br J Cancer* **1998**; 77: 2239-2245.
- Takahashi K**. Changes in the pulpal vasculature during inflammation. *J Endod* **1990**; 16: 92-97.
- Takahashi K**, MacDonald DG, Kinane DF. Analysis of immunoglobulin-synthesizing cells in human dental periapical lesions by *in situ* hybridization and immunohistochemistry. *J Oral Pathol Med* **1996**; 25: 331-335.
- Takahashi K**. Microbiological, pathological, inflammatory, immunological and molecular biological aspects of periradicular disease. *Int Endod J* **1998**; 31: 311-325.
- Tamura M**, Nagaoka S, Kawagoe M. Interleukin-1 alpha stimulates interstitial collagenase gene expression in human dental pulp fibroblast. *J Endod* **1996**; 22: 240-243.
- Teronen O**, Salo T, Konttinen YT, Rifkin B, Vernillo A, Ramamurthy NS, Kjeldsen L, Borregaard N, Hietanen J, Sorsa T. Identification and characterization of gelatinases/type IV collagenases in jaw cysts. *J Oral Pathol Med* **1995a**; 24: 78-84.
- Teronen O**, Salo T, Laitinen J, Tornwall J, Ylipaavalniemi P, Konttinen YT, Hietanen J, Sorsa T. Characterization of interstitial collagenases in jaw cyst wall. *Eur J Oral Sci* **1995b**; 103: 141-147.
- Teronen O**, Konttinen YT, Lindqvist C, Salo T, Ingman T, Lauhio A, Ding Y, Santavirta S, Valleala H, Sorsa T. Inhibition of matrix metalloproteinase-1 by dichloromethylene bisphosphonate (clodronate). *Calcif Tissue Int* **1997**; 61: 59-61.
- Teronen O**, Heikkilä P, Konttinen YT, Laitinen M, Salo T, Hanemaaijer R, Teronen A, Maisi P, Sorsa T. MMP inhibition and downregulation by bisphosphonates. *Ann N Y Acad Sci* **1999**; 30: 453-465.
- Teronen O**, Laitinen M, Salo T, Hanemaaijer R, Heikkilä P, Konttinen YT, Sorsa T. Inhibition of matrix metalloproteinases by bisphosphonates may in part explain their effects in the treatment of multiple myeloma. *Blood* **2000**; 96: 4006-4007.
- Tervahartiala T**, Pirilä E, Ceponis A, Maisi P, Salo T, Tuter G, Kallio P, Törnwall J, Srinivas R, Konttinen YT, Sorsa T. The *in vivo* expression of the collagenolytic matrix metalloproteinases (MMP-2, -8, -13, and -14) and matrilysin (MMP-7) in adult and localized juvenile periodontitis. *J Dent Res* **2000**; 79: 1969-1977.
- Thomas GJ**, Lewis MP, Hart IR, Marshall JF, Speight PM.  $\alpha_v\beta_6$  integrin promotes invasion of squamous carcinoma cells through up-regulation of matrix metalloproteinase-9. *Int J Cancer* **2001**; 92: 641-650.
- Thomas P**, Khokha R, Shepherd FA, Feld R, Tsao MS. Differential expression of matrix metalloproteinase and their inhibitors in non-small cell lung cancer. *J Pathol* **2000**; 190: 150-156.
- Tjäderhane L**, Salo T, Larjava H, Larmas M, Overall CM. A novel organ culture method to study the function of

- human odontoblasts in vitro: gelatinase expression by odontoblasts is differentially regulated by TGF-beta1. *J Dent Res* **1998**; 77: 1486-1496.
- Tjäderhane L**, Sulkala M, Sorsa T, Teronen O, Larmas M, Salo T. The effect of MMP inhibitor Metastat™ on fissure caries progression in rats. *Ann N Y Acad Sci* **1999**; 878: 686-688.
- Tjäderhane L**, Palosaari H, Wahlgren J, Larmas M, Sorsa T, Salo T. Human odontoblast culture method: the expression of collagen and matrix metalloproteinases (MMPs). *Adv Dent Res* **2001**; 15: 55-58.
- Torres JO**, Torabinejad M, Matiz RA, Mantilla EG. Presence of secretory IgA in human periapical lesions. *J Endod* **1994**; 20: 87-89.
- Tryggvason K**. The laminin family. *Curr Opin Cell Biol* **1993**; 5: 877-882.
- Tryggvason K**, Höyhty M, Pyke C. Type IV collagenases in invasive tumors. *Breast Cancer Res Treat* **1993**; 24: 209-218.
- Uitto VJ**, Airola K, Vaalamo M, Johansson N, Putnins EE, Firth JD, Salonen J, Lopez-Otin C, Saarialho-Kere U, Kähäri VM. Collagenase-3 (Matrix metalloproteinase-13) expression is induced in oral mucosal epithelium during chronic inflammation. *Am J Pathol* **1998**; 152: 1489-1499.
- Uitto V-J**, Overall C, McCulloch C. Proteolytic host cell enzymes in gingival crevice fluid. *Periodontol* **2000**; 2003; 31: 77-104.
- Uria JA**, Balbin M, López JM, Alvarez J, Vizoso F, Takigawa M, López-Otín C. Collagenase-3 (MMP-13) expression in chondrosarcoma cells and its regulation by basic fibroblast growth factor. *Am J Pathol* **1998**; 153: 91-101.
- Vaalamo M**, Weckroth M, Puolakkainen P, Kere J, Saarinen P, Lauharanta J, Saarialho-Kere UK. Patterns of matrix metalloproteinase and TIMP-1 expression in chronic and normally healing human cutaneous wounds. *Br J Dermatol* **1996**; 135: 52-59.
- Vaalamo M**, Mattila L, Johansson N, Kariniemi AL, Karjalainen-Lindsberg ML, Kahäri VM, Saarialho-Kere U. Distinct populations of stromal cells express collagenase-3 (MMP-13) and collagenase-1 (MMP-1) in chronic ulcers but not in normally healing wounds. *J Invest Dermatol* **1997**; 109: 96-101.
- Väänänen A**, Srinivas R, Parikka M, Palosaari H, Bartlett JD, Iwata K, Grenman R, Stenman UH, Sorsa T, Salo T. Expression and regulation of MMP-20 in human tongue carcinoma cells. *J Dent Res* **2001**; 80: 1884-1889.
- Vacca A**, Ribatti D, Presta M, Minischetti M, Iurlaro M, Ria R, Albini A, Bussolino F, Dammacco F. Bone marrow neovascularization, plasma cell angiogenic potential, and matrix metalloproteinase-2 secretion parallel progression of human multiple myeloma. *Blood* **1999**; 93: 3064-3073.
- Vaes G**, Delaissé JM, Eeckhout Y. Relative roles of collagenase and lysosomal cysteine-proteinases in bone resorption. *Matrix* **1992**; 1 (suppl): 383-388.
- Vartio T**, Vaheri A: A gelatin-binding 70,000-dalton glycoprotein synthesized distinctly from fibronectin by normal and malignant adherent cells. *J Biol Chem* **1981**; 256: 13085-13090.
- Vartio T**, Hovi T, Vaheri A. Human macrophages synthesize and secrete a major 95,000-dalton gelatin-binding protein distinct from fibronectin. *J Biol Chem* **1982**; 257: 8862-8866.
- Vihinen P** and **Kähäri VM**. Matrix metalloproteinases in cancer: prognostic markers and therapeutic targets. *Int J Cancer* **2002**; 99: 157-166.
- Vu TH**, **Werb Z**. Matrix metalloproteinases: effectors of development and normal physiology. *Genes & Development* **2000**; 14: 2123-2133.
- Walker KE**, Lappin DF, Takahashi K, Hope J, Macdonald DG, Kinane DF. Cytokine expression in periapical granulation tissue as assessed by immunohistochemistry. *Eur J Oral Sci* **2000**; 108: 195-201.
- Walton RE**, **Torabinejad M**. **Principles and practice in endodontics**. **WB Saunders, Philadelphia, USA . 1996.**
- Wernert N**, Raes MB, Lassalle P, Dehouck MP, Gosselin B, Vandebunder B, Stehelin D. C-ets 1 protooncogene is a transcription factor expressed in endothelial cells during tumor vascularization and other forms of angiogenesis in humans. *Am J Pathol* **1992**; 140: 547-557.
- Westerlund U**, Ingman T, Lukinmaa P-L, Salo T, Kjeldsen L, Borregaard N, Tjäderhane L, Konttinen YT, Sorsa T. Human Neutrophil gelatinase associated lipocalin in adult and localized juvenile periodontitis. *J Dent Res* **1996**; 75: 1553-1563.
- Wucherpfennig AL**, Li YP, Stetler-Stevenson WG, Rosenberg AE, Stashenko P. Expression of 92kD type IV collagenase/gelatinase B in human osteoclasts. *J Bone Miner Res* **1994**; 9: 549-55
- Ylipaavalniemi P**. Proteins in jaw cysts. Dissertation. Helsinki: University of Helsinki. **1978.**